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Abstract
Rapid and potent expression of the pro-inflammatory cytokine, interleukin (IL)-1β, is a
unique characteristic of macrophages. Enhancers are distal regulatory elements that promote
gene expression in a cell-type specific manner. PU.1 is a lineage-determining transcription
factor that regulates myeloid-specific genes by activating distal enhancers. To date, how
macrophages rapidly and potently express IL-1β is not well understood. This study identifies
a potential enhancer of IL-1β, and how PU.1 regulates its activity state in macrophages and
non-myeloid cells. Enhancers are demarcated by unique histone modifications: high in
H3K27Ac and H3K4me1, and low in H3K4me3. Based on the ChIP-seq data available from
the ENCODE database, I found a genomic region located ~10 kbs upstream of the IL-1β TSS
with these histone signatures. I hypothesize that the genomic region is an enhancer that
regulates the expression of IL-1β mRNA in a PU.1-dependent manner in murine
macrophages. A putative enhancer RNA (eRNA) was transcribed from the enhancer, and
knock-down of the eRNAs with antisense oligonucleotides inhibited IL-1β production.
Furthermore, through chromatin conformation capture (3C) analysis, enhancer-promoter
interactions were detected in macrophages stimulated with the bacterial cell component
lipopolysaccharide (LPS), confirming that the genomic element was an IL-1β enhancer.
Overexpression of PU.1 in non-myeloid B16-BL6 cells induced IL-1β enhancer-promoter
interaction, and promoted the expression of IL-1β mRNA and eRNAs upon LPS exposure.
Enhancer knock-out by the CRISPR-Cas9 system reduced IL-1β expression in these cells. In
summary, this study indicates that PU.1 alters the chromatin architecture which allows rapid
and potent expression of IL-1β eRNAs and mRNA.
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CHAPTER 1

1

INTRODUCTION

1.1

Macrophage Differentiation

Macrophages are effector cells that have essential homeostatic and immunological roles
in humans [1,2]. They are best known as sentinel innate immune cells that are responsible
for detecting and killing foreign pathogens via phagocytosis [1-3]. Additionally,
macrophages partake in generating rapid immune responses against invading
microorganisms by producing various pro-inflammatory cytokines [4,5]. In addition to
their immunological roles, their involvement in maintaining tissue homeostasis also
needs recognition. Contribution to tissue and organ homeostasis is exemplified by their
function as a janitorial cell that removes erythrocytes, cellular debris, and apoptotic and
senescent cells [1]. Due to their anatomical location and physiological function,
macrophages are often classified as a member of the mononuclear phagocytosis system
(MPS) along with monocytes and dendritic cells [6]. Within this mononuclear phagocytic
lineage, tissue-resident macrophages are considered as terminally differentiated cells that
originate from circulating monocytes [2]. As circulating monocytes migrate into various
tissues from the bloodstream, they undergo differentiation to become resident
macrophages and perform specialized functions according to the microenvironment
[2,5,7]. For example, osteoclasts are primarily involved in bone remodeling, and the
absence of these specialized macrophages can result in osteoporosis and osteopetrosis
[2,7]. Alveolar macrophages equipped with pattern recognition receptors (PRRs) and
scavenger receptors on the surface are necessary for efficient clearance of
microorganisms in the lung [7]. Thus, cells of the MPS, particularly macrophages, exhibit
remarkable heterogeneity and plasticity [5,7]. Recently, the Immunological Genome
(ImmGen) project (https://www.immgen.org/) has been launched to address whether or
not the phenotypic and functional variance of tissue-resident macrophages are the result
of unique gene expression profiles [8]. Analyses of the gene expression patterns of
several populations of macrophages including peritoneal, splenic, and alveolar
macrophages have shown that the expression levels of only a few selective genes, such as
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MerTK, Toll-like receptor (TLR) 4, TLR7, TLR8, and TLR13, remained uniform across
all populations [8]. These data indicated that the ability of macrophages to efficiently
adapt to their surroundings and generate cell-type specific responses against external
stimuli is a reflection of their variance in gene expression profiles.

1.1.1

Classically-activated vs. alternatively-activated macrophages

Macrophages express diverse classes of surface receptors such as PRRs, scavenger
receptors, phosphatidyl serine receptors, integrins, and complement receptors that are
required for their function [9]. Expression of such wide range of surface receptors allows
macrophages to exhibit remarkable plasticity in nature. Based on their characteristics in
producing inflammatory and immunoregulatory responses, a binary classification system
is often used to distinguish macrophage activation states: classically-activated (M1) and
alternatively-activated (M2) macrophages [1,5,10,11]. Microbial products such as
lipopolysaccharide (LPS), and the inflammatory cytokines interferon (IFN)-γ, and tumor
necrosis factor (TNF)-α induce macrophages to polarize toward M1 macrophages. M1
macrophages promote inflammation by secreting pro-inflammatory cytokines such as
interleukin (IL)-1β, IL-6, and IL-23 and anti-microbial molecules such as reactive oxygen
species (ROS) and nitrogen radicals [1,5,10]. In contrast, exposure of macrophages to IL4, and IL-13 generates M2 macrophages that induce anti-inflammatory responses or have
wound healing capabilities [1,5,10]. The contrasting characteristics of M1 and M2
macrophages are likely the result of unique gene expression profiles. Despite many genes
that are co-upregulated or co-downregulated in macrophages of both activity states, there
are multiple genes that are exclusively induced in one type of macrophages while
suppressed in the other [11]. For example, it has been reported that N-formyl peptide
receptor 2 (Fpr2) and cluster of differentiation 38 (CD38) are greatly enhanced in M1
macrophages [11]. Fpr2 is a G-protein coupled receptor that recognizes bacteria-derived
N-formyl methionyl peptides, resulting in increased chemotaxis and ROS production by
macrophages; whereas, CD38 is a glycoprotein that catalyzes the synthesis of key
messengers of calcium signaling, cADP-ribose and ADP-ribose, from NAD+ [11]. On the
other hand, early growth response protein 2 (Egr2) is a gene that tends to be specifically
upregulated in M2 macrophages [11]. Egr2 is a transcription factor (TF) that is closely
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linked to cell proliferation, tumour suppression, and peripheral nerve myelination [12].
This particular TF also induces the generation of macrophage colony-stimulating factor
(M-CSF) receptor, which is involved in the generation of anti-inflammatory macrophages
[12,13].

1.1.2

Signaling pathway activated by LPS

LPS is a main constituent of the outer membrane of Gram-negative bacteria. LPS sledded
from bacteria that enter the bloodstream of the host are detected by LPS-binding proteins
(LBPs) [14,15]. LBP traffics LPS to CD14, which functions as a co-receptor that presents
LPS monomers to the TLR4 and lymphocyte antigen 96 (MD2) complex [14,16,17].
Binding of phosphate and acyl groups of LPS to TLR4 and MD2, respectively, induces
the dimerization of TLR4-MD2 complex that triggers intracellular signaling cascades
through the toll/IL-1 receptor (TIR) domain [14]. TIR recruits one of the TIR containing
adaptor proteins known as myeloid differentiation factor (MyD) 88, through interacting
with another TIR containing adaptor protein, MyD88-adapter-like (Mal) [18]. Interaction
between TLR4s and MyD88 initiates a cascade of signaling events that activates nuclear
factor (NF)-κB [14]. At steady state, NF-κB is localized in the cytoplasm due to the
cytosolic protein inhibitor κB (IκB) [19]. The signal transduction triggered by LPS causes
degradation of IκB that leads to translocation of NF-κB to the nucleus and initiation of
transcription [14]. In addition, TLR4 activates the MyD88-independent pathway, which
is mediated by another TIR motif containing adaptors, known as TIR domain-containing
adapter inducing interferon (TRIF) and TRIF-related adapter molecule (TRAM). The
signaling cascade activated by these adaptors leads to the activation of NF-κB, IFN
regulatory factor (IRF) 3 and IRF7 [17,20]. IRF3 and 7 promote the synthesis of IFN-α
and -β that bind to their respective cognate receptors on the macrophages [20]. Activation
of IFN receptors triggers the Janus kinases (JAKs)/ Signal transducer and activator of
transcription (STAT) signaling cascade that induces expression of genes involved in antiviral responses and caspase-11 [20,21]. Caspase-11 mediates NLRP3-induced cleavage
of pro-caspase-1 into caspase-1 [21]. Caspase-1 is also known as the IL-1β-converting
enzyme that converts biologically inactive pro-IL-1β to its active form [22].
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1.2

IL-1β

The IL-1 family of cytokines are crucial elements of the innate immune system that can
either initiate or suppress inflammation [22]. It comprises 11 members, which include IL1α, -1β, -1Ra, -18, -1H4, -1H2, -1ε, -1HY2, -33, FIL1δ, and FIL1ε, with diverse roles in
immune responses. For example, IL-1α and -1β are potent pro-inflammatory cytokines;
whereas IL-1Ra, FIL1δ, and IL-1H4 have anti-inflammatory roles [22,23]. Amongst the
IL-1 cytokines, IL-1β has been studied most thoroughly, and many reports highlight its
role in various cellular processes such as cell differentiation, autophagy and apoptosis,
and immune activation through T lymphocytes [24-27]. Despite the importance of IL-1β
in the innate immune system, failure to control the intensity and duration of its expression
can cause the development of autoinflammatory diseases, as it is closely associated with
local and systemic inflammation [22,28]. Autoinflammatory diseases are a class of
clinical disorders that arise due to dysregulation of the innate immune system, often
resulting in chronic inflammation [22,29]. Most notably, familial cold autoinflammatory
syndrome (FCAS), gout, type 2 diabetes, and Muckle-Wells syndrome are examples of
IL-1β-associated autoinflammatory diseases [22,29]. Thus, IL-1β serves as a good
therapeutic target to treat atherosclerosis and type 2 diabetes, as well as other
inflammatory diseases [30-32].

1.3
1.3.1

Gene Regulation
Regulatory Elements

It is well established that each cell has a unique gene expression profile that determines
its phenotype and allows to perform biological functions. Also the expression of genes
must be tightly controlled, as dysregulation can give rise to various diseases. There are
multiple regulatory elements that corporately regulate transcription. For example, core
promoters are generally defined as nucleosome-depleted and DNaseI hypersensitive
regions that encompass multiple elements such as the transcription start site (TSS) and
the TATA box [33,34]. These proximal regulatory entities serve as the platform for the
basal transcriptional machinery and the designated site of pre-initiation complex
assembly [33,34]. Ultimately, promoters function in concert with distal regulatory
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elements that either suppress or activate transcription of the target gene [35]. A large
portion of mammalian genome is non-coding regions that were once considered as ‘junk
sequences’ [36]. However, these non-coding regions contain functional distal regulatory
elements which are now regarded as key players of gene regulation. Enhancers are distal
regulatory elements that positively regulate and enhance transcription of cognate genes in
a spatiotemporal manner [33]. Similar to promoters, enhancers also recruit the
transcriptional machinery and produce transcripts commonly referred to as enhancer
RNAs (eRNAs) [37]. In addition, silencers and insulators are regulatory elements that
serve as negative regulators of gene expression [33]. Within the genome, silencers, which
are docking sites for repressors, can be positioned either away from or within proximal
promoters [33]. Insulators also serve as negative regulatory elements that are renowned
for their two functions: barrier function (prevent decompaction of chromatin) and
enhancer blocking [36,38]. Notably, insulators can block the activity of enhancers by
preventing the formation of inter- and intra-chromosomal interaction between enhancers
and irrelevant genes [36]. Altogether, the interplay of positive and negative regulatory
elements as well as various transcription factors dictate the gene expression profile of a
cell.

1.3.2

Epigenetics

Gene regulation is not limited to the activity of regulatory elements; but also controlled
by epigenetics, which is defined as inheritable regulation of gene expression without
changes in the DNA sequence [39]. Amongst many epigenetic processes, DNA
methylation is one of the most thoroughly studied [39]. Generally, DNA methylation is
known to have a robust inverse relationship with chromatin accessibility [40].
Methylation of DNA is mediated by DNA methyltransferases (DNMTs), a family of
proteins that transfers methyl groups to cytosine in CpG dinucleotides (cytosine directly
linked to guanosine via phosphodiester bond) in mammals [39,41]. Specifically, methyl
groups are added to the C5 position of cytosine, forming 5-methylcytosine (5mC) [39]. It
is widely accepted that 5mC is a methylation marker that has a repressive effect on gene
expression [41,42]. For example, Hashimoto et al. demonstrated that chemical treatment
(IL-1β or TNF-α ± oncostatin M or 5-aza-deoxycytidine) of human articular
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chondrocytes induced the production of IL-1β mRNA and protein [43]. Intriguingly, they
observed a significant reduction in the methylation of CpG sites in the promoter of IL-1β
[43], suggesting that the methylation status of the gene is an epigenetic marker that
regulates its production. Likewise, the methylation status of enhancers has also been
shown to contribute in gene regulation; and ultimately be involved in disease progression
and cancer development [44]. Monomethylation of histone (H) 3 lysine (K) 4
(H3K4me1), a unique chromatin signature of enhancers, is associated with DNA
hypermethylation [45]. In addition, DNA methylation negatively correlates with
acetylation of H3K27 (H3K27Ac), which demarcates active enhancers, [45]. Specifically,
hypermethylation of DNA results in diminished levels of H3K27Ac at enhancers [45,
46], and essentially reduces the activity of these distal regulatory elements [47]. There are
currently two mechanisms suggested for DNA demethylation. In passive DNA
demethylation, loss of methyl groups occurs in cell replication-dependent manner, and
daughter cells inherit less methylated DNA due to inhibition of DNMTs [41,48,49,50].
Active DNA demethylation occurs independently of cell replication and is a more rapid
process that involves direct removal of the methyl groups. Initially, ten-eleven
translocation (TET) protein converts 5mC to 5-hydroxymethylcytosine (5hmC), an
intermediate form of oxidized 5mC [49]. 5hmC can be further oxidized into metabolites
such as 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC) by TET proteins, in which
the resulting products are fixed via base excision repair facilitated by thymine DNA
glycosylase [48,51,52].
Post-translational modification (PTM) of histones is another notable epigenetic
mechanism that is essential for gene regulation [44]. Histones are positively charged
nuclear proteins that closely associate with negatively charged DNA to form chromatin
[53]. Initially, 147 base pairs of DNA are wrapped around histone octamers that consist
of two H2A-H2B dimers and one H3-H4 tetramer [53]. Supercoiling of DNA around the
histone octamer forms the basic unit of DNA compaction, nucleosomes [53,54]. The Ntermini of H2B, H3, H4, and C-terminus of H2A, commonly referred to as histone tails,
tend to protrude from nucleosomes, and are prone to various PTMs such as methylation,
acetylation, phosphorylation, ubiquitination, SUMOylation, ADP ribosylation, and
deamination [54]. Formation of nucleosomes for the purpose of DNA compaction is
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undoubtedly important; however, such tight packaging of the DNA can limit accessibility
by various TFs and interfere with proper gene expression [55]. Thus, remodeling of
nucleosomes mediated by PTMs such as methylation, acetylation, and phosphorylation is
necessary to overcome such structural complications [55].
Histone tails are enriched in positively charged K and arginine (R), which are subject to
methylation [55,56]. Histone methylation involves the transfer of methyl groups from Sadenosylmethionine to the ε-amino group of K and ϖ-guanidino group of R by lysine
methyltransferases and arginine methyltransferases, respectively [56]. Although both
amino acids can be methylated, K4, 9, 27, and 36 of H3 and K20 of H4 are considered as
the most common substrates for methylation [57]. Lysine residues can be methylated to
varying degrees (mono-, di-, tri-), which affect the hydrophobic and steric properties of
the amino acid [58]. The three degrees of methylation marks at specific K residues serve
as docking sites for various effector proteins, and can dictate the role of lysines as either
activators or repressors of gene expression [58]. For example, monomethylation of H3K4
H3K4, H3K36, and H3K79 are associated with transcriptional activation, whereas higher
degrees of methylation at H3K9, H3K27, and H4K20 are involved in repressive gene
expression [59]. Interestingly, methylated lysine residues may have further contributions
in gene regulation by serving as specific markers of proximal and distal regulatory
elements. For example, combination of H3K4me1 and H3K4me3 are characteristics that
are considered when defining proximal promoters and distal enhancers, as unique ratios
of these epigenetic signatures are conserved at these regulatory elements across the
genome [47,60,61]. High and low levels of H3K4me1 and H3K4me3 (H3K4me1hi,
H3K4me3low) are recruited at distal enhancers while the inverse ratio (H3K4me1low,
H3K4me3hi) of these histone modifications are observed at proximal promoters [60,61].
Histone acetylation is a reversible PTM that correlates with active gene expression by
promoting the formation of euchromatin and increasing DNA accessibility [62]. Unlike
histone methylation, acetylation of K residues neutralize the charge of the histone tails
[63]. Acetylation-mediated loss of charge can disrupt the interaction between histones
and DNA, essentially causing the chromatin to take on an ‘open’ conformation [44,63].
The transfer of acetyl group from acetyl Coenzyme A (acetyl-CoA) to the ε-amino group
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of K is catalyzed by histone acetyltransferases (HATs) [63]. HATs are multisubunit
protein complexes that can be classified as either cytoplasmic proteins that acetylate
newly synthesized histones prior to nuclear translocation or nuclear proteins that
promotes addition of acetyl groups to histone tails [63]. There are five subclasses of
HATs: general control nonderepressible 5 (Gcn5)-related acetyltransferases (GNATs);
MOZ, Ybf2/Sas3, Sas2, Tip60 (MYST)-related HATs; p300/CREB-binding protein
(CBP) HATs; general transcription factor HATs (TFIID subunit TAF250); nuclear
hormone-related (steroid receptor coactivator 1/3) HATs [64]. Although the HAT domain
responsible for interacting with CoA is conserved in all subclasses, substrate specificity
of HATs still varies between and within subclasses, as each HAT complex comprises
distinct combinations of domains and subunits [64]. For example, GNATs that contain
Gcn5 alone preferentially acetylates H3K14, while the accessory protein, Ada, modifies
H3K9, 14, and 18 [64]. Similar to histone methylation marks, acetylation of specific K
residues can also be utilized as markers of regulatory elements. p300/CBP HATs are
homologous proteins that serve as transcriptional co-activators [65]. These histone
modifiers are often recruited to enhancers, and can acetylate all four types of histones
[65]. Specifically, previous studies reported that p300/CBP are capable of catalyzing the
acetylation of H3K27 (H3K27Ac), a unique marker of active enhancers [66,67].
The level of histone acetylation is maintained by the interplay of HATs and histone
deacetylases (HDACs) [63]. HDACs are responsible for the removal of acetyl group from
the K residues, resulting in hypoacetylation of histone tails that strengthens the
interaction between histones and DNA [63]. HDACs can be classified into either the
classical (Zn2+-dependent) or SIR2 (silent information regulator 2; NAD+-dependent)
families [63]. The classical HDACs are subdivided into Class I (HDAC 1, 2, 3, 8), Class
II (HDAC 4-7, 9, 10), and Class IV (HDAC 10) [63]. These metal-dependent
deacetylases have activation sites that require Zn2+ as the cofactor [63]. Class I HDACs
are primarily localized and active in the nucleus, whereas most class II HDACs exist
within the cytoplasm [63,68]. Although HDAC10 (class IV) is the least studied amongst
all HDACs, the current understanding is that it has roles in both nuclear and cytoplasmic
compartments [68]. There are 7 Sir2 family members (SIRT1-7) that belong in class III
of deacetylases [68]. Sir2 HDAC-mediated deacetylation of K residues involves the
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transfer ADP-ribose from NAD+ to acetyllysine [68]. This particular class of HDACs are
distributed throughout the entire cell and are localized in the nucleus, cytoplasm, as well
as mitochondria [68]. In general, HDACs do not repress gene expression alone, but rather
work in concert with other repressor proteins like DNA methyltransferases [63].

1.3.3

Chromatin Organization

All cellular activities that govern physiological and homeostatic events in the body are
dictated by the genetic information stored in the DNA. The entire human genome, which
can span 2 meters in length, must be tightly organized in order to be packed in the
nucleus of a single cell (Fig. 1.1). The formation of nucleosomes is the initial step of
DNA compaction that reduces the length of the genome by approximately 7-fold [54].
Then, the chromosomes are segregated into distinct chromosome territories, which allow
intra-chromosomal interactions to form while communication between chromosomes
becomes less preferred [54,69]. Within the chromosome territories, the chromosomes are
partitioned into either open (“A”) or closed (“B”) regions [54]. The open compartment is
occupied by DNA segments that are enriched in genes, regulatory elements, and various
features that mark active transcription, whereas closed compartments consist of
transcriptionally repressive genomic regions [54]. The DNA in A and B compartments
are then further segregated into topologically associating domains (TADs), which
organize co-expressed genes into distinct regions [54,70]. Despite being positioned in
different chromosomes, genes within TADs can be subjected to transcriptional activation
mediated by trans-acting enhancers that exist in the same TADs via intermolecular
interactions [54]. The DNA segments in TADs tend to be on average ~800 kb in length,
and these genomic entities are retained throughout cell differentiation [70-72].
Interestingly, the nuclear positions of these TADs tend to be conserved across species
including humans, mouse, and fruit flies [71]. Finally, TADs can be partitioned into subTADs, in which these subdomains tend to vary between cell types [54].
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Figure 1.1. Packaging of the genome in the nucleus occurs in a hierarchical manner.
At the top of the hierarchy, chromosomes are initially organized into distinct regions in
the nuclear space (chromosome territories – different coloured regions in the nucleus),
where the genome is further partitioned into transcriptionally active (A) or repressive (B)
compartments. Within each compartment, TADs (red circular region) and sub-TADs
(small green circular regions within TADs) are formed, allowing chromatin loopingmediated interaction between regulatory elements such as enhancers, silencers, and
insulators with the promoters of target genes to occur.
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1.4

Distal regulatory element: Enhancers

Enhancers are cis- and trans-acting regulatory elements that engage with promoters over
long distances to promote gene transcription in a cell-type specific manner [42,73,74]. As
above-mentioned, unique gene expression profiles are determined by combinatory
activities of different regulatory elements [75]. Recent studies showed that more than 1
million putative enhancers, which greatly exceeds the number of coding genes, have been
identified in the human genome [76,77]. These enhancers are hypersensitive to DNases,
indicating euchromatin status of their chromatin landscapes. The lineage-determining
transcription factors (LDTFs) are crucial proteins that bind specific motifs within
enhancers and promote a shift in chromatin architecture from heterochromatin to
euchromatin via ATP-dependent nucleosome remodelers [42,73,74,76]. Subsequently,
co-activators, p300/CBP, are recruited to the readily accessible enhancers [42,74]. These
histone modifiers induce epigenetic reprogramming of nucleosomes that flank the
enhancer domains [73]. When enhancers are activated, TFs and RNA polymerase II
(RNAPII) are recruited to the enhancers, resulting in dynamic transcription of eRNAs
[42,73,77-81]. However, the mechanisms of how enhancers promote gene transcription
are not fully understood. It is speculated that enhancers promote transcription by
recruiting the pre-initiation complex and releasing RNAPII from the promoter to move
along the DNA [74].

1.4.1

Epigenetic signatures of enhancers

DNA segments with chromatin signatures H3K4me1hi and H3K4me3low were originally
defined as enhancers, whereas higher levels of H3K4me3 compared to H3K4me1 were
recruited at active promoters [42,60,82]. Dissimilar to the invariant binding patterns of an
insulator protein CCCTC-binding factor (CTCF), the locations of H3K4me1-marked
enhancers are different across many cell types [60]. Additionally, cells also display
highly distinct distribution patterns of DNase-hypersensitive and p300-binding sites
[60,83]. These results indicate that the association of nucleosome-depleted genomic
regions with H3K4me1 and p300 is a marker for cell-type specific enhancers. It was also
shown that H3K4me1 is deposited at potential enhancers prior to nucleosomal depletion
and enrichment of H3K27Ac [84]. In some cases, H3K4me1 remains bound to enhancers

13

following the dissociation of H3K27Ac, a unique histone modification of active
enhancers [85]. The difference in the dynamics of these histone modifications suggest
that H3K4me1 is an epigenetic marker of both active and poised enhancers [60,86].
As previously mentioned, co-activators like p300 and CBP are HATs that are recruited to
enhancers and acetylate H3K27 [42,66,67,87]. Further studies confirmed that H3K27Ac
demarcates active enhancers [82,85]. HAT-mediated acetylation of H3K27 plays a
central role in promoting the release of RNAPII. Upon acetylation, bromodomaincontaining protein (Brd) 4, a member of the bromodomain and extra terminal domain
(BET) family of proteins, binds to acetylated K residues of histone H3 and H4 [88,89].
The association of Brd4 with acetylated histones is followed by the recruitment of the
positive transcription elongation factor (P-TEFb) and the Mediator complex [90]. Brd4
converts P-TEFb into an active form that leads to the phosphorylation of negative
elongation factor (NELF) complex and DRB sensitivity inducing factor (DSIF), which
directly interact with RNAPII to hold the polymerase at the promoter region [91,92].
Furthermore, P-TEFb also phosphorylates Serine 2 (Ser2) of carboxy terminal domain
(CTD) of RNAPII, a modification that indicates the transition of a polymerase from the
pause to the elongation phase [91,93]. Kaikkonen et al. demonstrated this phenomenon in
macrophage enhancers as elevated levels of Ser2P RNAPII are observed near the
nucleosome free regions post stimulation with the TLR4 agonist Kdo2-Lipid A [91].
Therefore, a method in identifying active enhancers is through examining the H3K4me1,
H3Kme3, and H3K27Ac markers.

1.4.2

Lineage-determining transcription factors of macrophage
enhancers

The plastic nature of macrophages that allows the cells to achieve diverse functional
states in response to various microenvironments is mediated by enhancers, which
promote the expression of specific genes [94]. Amongst several hematopoietic TFs, PU.1
plays a central role in the development of macrophages and B cells [95]. PU.1 is a
member of the Ets family of proteins that specifically recognize and bind to purine-rich
motifs of DNA [96,97]. PU.1 has four domains with distinct characteristics and functions
[98,99]. The acidic domain and the adjacent glutamine (Gln)-rich domain make up the N-
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terminus half of PU.1. These domains are essential for PU.1’s capacity to transactivate
genes [98,100]. The C-terminus consists of the DNA-binding domain which is
homologous across the entire Ets family of proteins [98]. The PEST domain spans the
middle of PU.1 and is necessary for interaction with other proteins like PU.1-interacting
partner (Pip) in B cells [98,101]. The role of PU.1 in rendering B cell- or macrophagelineage commitment is dependent on the intracellular concentration of PU.1, where a high
level of PU.1 is required for macrophage differentiation [102]. It was shown that PU.1
drives progenitor cells toward the macrophage lineage by selectively binding to
macrophage-specific enhancers [103]. Furthermore, studies discovered that PU.1 bound
H3K4me1-marked genomic regions in macrophages, whereas the binding pattern of PU.1
differed in B cells of various developmental stage [103,104]. PU.1-bound regions are also
occupied by p300, fulfilling a criterion that is often used for identifying enhancers [103].
Thus, PU.1 shapes cellular identity of macrophages via selectively binding to enhancers
that promote expression of macrophage-specific genes. However, gene expression
profiles of macrophages are not dictated by PU.1 alone, but rather in concert with other
TFs including CCAAT/enhancer binding protein (C/EBP) family of proteins and AP-1
[104-106]. It has been shown that PU.1-bound enhancer regions also contained binding
motifs for C/EBP and AP-1, resulting in co-localization of these TFs with PU.1
[104,105]. Moreover, despite the importance of graded concentration of PU.1 in
macrophage differentiation, the ratio of PU.1 to C/EBPα concentrations should also be
taken into account, as high levels of C/EBPα can drive granulocyte and neutrophil
development [107,108]. Therefore, macrophage differentiation is not determined solely
by PU.1 but also its association and cooperation with other TFs.

1.4.3

eRNAs

Transcripts produced from active enhancers, eRNAs, are another considerable factor of
gene regulation. eRNAs are a subclass of non-coding RNAs that are uni- or bidirectionally transcribed by RNAPII and other components of the transcriptional
initiation complex, which have been recruited to readily accessible enhancers [42].
Dissimilar to mRNA, majority of eRNAs do not acquire a poly(A) tail; hence, half-life of
eRNAs tends to be shorter than that of mRNAs [42,73]. Regardless, rapid and dynamic
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production of eRNAs by extracellular stimuli prompted investigators to examine the
functional importance of eRNAs in gene regulation. Li et al. showed that knock-down of
eRNAs with small interfering (si)RNAs and LNAs resulted in diminished levels of TFF1,
FOXC1, and CA12 in 17β oestradiol-exposed MCF-7 cells [80]. Although the functional
importance of eRNAs has been demonstrated, the mechanisms by which eRNAs regulate
gene expression remain elusive. A potential mechanism of eRNA is its ability to promote
RNAPII release from its pause phase by interacting with the NELF-DSIF complex [109].
NELF-DSIF complexes associate with nascent RNA through RNA recognition motif
(RRM) in NELF, which accounts for the repressive function of the protein [109].
Schaukowitch et al. demonstrated that NELF is readily released from Arc and Gadd45b
promoters in depolarized neurons; however, knock-down of eRNAs transcribed from
enhancers located ~7 kilobases (kbs) upstream and downstream of Arc and Gadd45b,
respectively, inhibited NELF dissociation from the promoters [109]. Subsequently, they
also showed that NELF-E, a subunit of NELF that carries the RRM sequence, directly
bound to Arc and Gadd45b eRNAs through pull-down assay [109]. This suggested that
eRNAs compete with nascent RNA to interact with NELF via RRM, causing it to
dissociate from RNAPII [109]. Moreover, another mechanism by which eRNAs affect
the transcriptional output is through the recruitment of the Mediator complex at the
promoter region of target genes [110,111]. It was shown that eRNAs physically interact
with the Mediator complex subunit (MED) 1 and MED12 subunits of the Mediator
complex, and siRNA-mediated knock-down of eRNAs directly reduced the colocalization of the Mediator and RNAPII at the respective promoter region [110,111].
Furthermore, as enhancer-promoter interactions have been detected in many studies, the
functional role of eRNAs in facilitating chromatin looping between enhancers and
promoters was examined. Studies have shown that the frequency of spatial interactions
between enhancers and promoters is significantly reduced upon depletion of eRNAs
[80,110,111]. In line with eRNA-mediated formation of enhancer-promoter interactions,
the Mediator complex behaves in a similar manner, as knock-down of MED1 and
MED12 subunits inhibits chromatin looping between regulatory elements [110].
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1.4.4

Physical association of enhancers and promoters

Enhancers are remotely positioned from their cognate genes. The distance between these
genomic elements can extend as far as 2-3 Mbs. In order for enhancers to positively
regulate gene expression, they must be in proximity with their target promoters
[42,74,112]. Chromatin looping is a proposed model describing the interaction between
distal regulatory elements and promoters in the nuclear space by extruding the
intervening DNA [42,74]. In addition to eRNAs and the Mediator complex discussed
above, major structural remodelers of the genome include CTCF and cohesin [113-116].
CTCF is an insulator protein that is largely deposited at borders of TADs [117]. Not only
does this protein segregate active genetic segments from the inactive by sorting them into
different compartments, it also has the ability to either activate or repress gene expression
via enhancer blocking activities [117]. Notably, CTCF is a strong determinant of
enhancer-promoter interactions along with cohesin, a protein complex structured like a
ring [114,116,117]. Cohesin is primarily responsible for sister chromatid cohesion during
DNA replication; however, it has been reported that cohesin associates with CTCF to
remodel the chromatin landscape, and depletion of either protein attenuates the
interaction frequency between enhancers and promoters [113,114,118,119]. In addition,
cohesin is also known to co-localize with the Mediator complex [119]. Collectively, these
findings infer that the interplay of various chromatin remodelers is crucial for the
dynamic organization of the genome.

1.4.5

Detection of enhancer-promoter interactions via Chromosome
Conformation Capture (3C) analysis

The most widely applied technology to analyze the genome architecture is 3C and its
derivative high-throughput experiments such as 4C (circularized 3C-seq), 5C (3C-carbon
copy) and Hi-C [120]. These techniques are favoured over other genome visualization
techniques like light microscopy due to its sensitivity [121]. Additionally, another
noteworthy advantage of 3C is that it can quantitate the interaction frequency of DNA
segments in the nuclear space. Fig. 1.2 outlines the overall procedure of 3C analysis,
which has been employed throughout this study to examine the intra-chromosomal
interaction of the proposed enhancer and the IL-1β promoter. Initially, DNA regions in
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proximity are crosslinked via formaldehyde fixation [120-123]. Following the isolation of
the nuclei, fixed chromatins are exposed to restriction enzymes [120-123]. The choice of
restriction enzyme should be carefully considered to obtain proper sizes of DNA
fragments and avoid cleavage of the gene areas of interest [122]. Subsequently, ligation
of digested DNAs is performed with preference of ligation between DNAs in close
proximity [120-123]. Finally, the ligated products are de-crosslinked and purified to
generate a collection of adjoined DNA segments commonly referred to as 3C library
[122]. Quantification of 3C library is performed via real-time quantitative (q)PCR assays.
Since a vast number of different combinations of ligated DNAs is generated in a given
3C library, a specific ligation event can be very rare and occur 1/2000 to 1/20000 of the
time [122]. Therefore, utilization of a sequence specific double-dye qPCR methods, such
as TaqMan probes, rather than dye-based methods (SYBR Green), will increases the
specificity of 3C analysis [122].
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Figure 1.2. Workflow of 3C analysis. The interacting DNA regions, particularly
regulatory elements such as the promoter (orange box) and the enhancer (blue box) of a
gene, are positioned in close proximity in the nuclear space via chromatin looping. The
regulatory elements are crosslinked by formaldehyde (small red circles), followed by
restriction enzyme digestion (black arrows) to cleave and remove any intervening DNA.
The restriction enzyme-mediated cleavage of the DNA leaves either overhangs or blunt
ends (represented as different coloured boxes at the ends of each DNA fragment), which
are then re-ligated. Ligation of the crosslinked DNA regions generates target fragments in
opposite orientations that can be amplified via qPCR.
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1.5

Rationale, Hypothesis, and Research Aims

Enhancers are genomic regulatory elements that determine the characteristics of each cell
type. PU.1 is a LDTF that plays a key role in macrophage generation and differentiation
by activating enhancers. Enhancers are often demarcated by unique histone
modifications: H3K27Achi, H3K4me1hi, H3K4me3low. Based on these histone signatures
available from the Encyclopedia of DNA Elements (ENCODE:
https://genome.ucsc.edu/encode/) database, I identified a genomic region located ~10 kbs
upstream of the IL-1β TSS as a potential enhancer (Fig. 3.1). I hypothesize that the
genomic region is an enhancer that regulates the expression of IL-1β mRNA in a PU.1dependent manner in murine macrophages. Based on this hypothesis, I have proposed the
following research aims:
Aim I – Identifying the active enhancer of IL-1β in murine macrophages
Aim II – Examining the role of PU.1 in the enhancer-promoter regulatory network of IL1β
Aim III – Elucidating the role of PU.1 domains in the IL-1β regulatory network
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Chapter 2

2

Materials and Methods

2.1

Reagents

Dulbecco’s modified eagle medium (DMEM) and RPMI-1640 medium used to culture
RAW264.7 macrophages and B16-BL6 melanoma cells, respectively, were purchased
from Sigma Aldrich. Transfection reagents, Lipofectamine RNAiMAX and Polyjet, were
obtained from Invitrogen and SignaGen Laboratories, respectively. PowerUPTM SYBR®
Green Master Mix was from Applied Biosystems while dual-labeled Taqman probe (dye:
JOE) and Hot Start Taq DNA polymerase were from Integrated DNA Technologies and
New England Biolabs. Scrambled and eRNA-specific ASO were obtained from Exiqon.
The primers used for qPCR assays were purchased from Eurofins genomics. QX200TM
ddPCRTM EvaGreen supermix and droplet generation oil for EvaGreen were obtained
from Bio Rad. The reagents utilized for 3C analysis include: Formaldehyde (VWR),
DpnII, T4 DNA Ligase, and T4 DNA Ligase Buffer were from New England Biolabs,
RNase (Qiagen), Proteinase K and Phenol:Chloroform:Isoamyl Alcohol (PCI) were
purchased from Invitrogen.

2.2

Cell culture and Transfection

RAW264.7 macrophages were cultured in DMEM (high glucose) that contains 8% fetal
bovine serum (Sigma – Aldrich), 10 mM MEM non-essential amino acids, 1 mM sodium
pyruvate, 100 IU/mL penicillin, and 100 µg/mL streptomycin. B16-BL6 melanoma cells
were cultured in RPMI-1640 medium that contains 10% fetal bovine serum (Sigma –
Aldrich), 10 mM MEM non-essential amino acids, 1 mM sodium pyruvate, 100 IU/mL
penicillin, and 100 µg/mL streptomycin. Throughout transfection of B16-BL6 cells with
the transfection reagent, Polyjet, the cells were cultured in DMEM (high glucose, 10%
FBS) containing all of the aforementioned components. All cells were cultured in an
incubator with an optimal temperature of 37oC and CO2 level of 5%.
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2.2.1

Transfection of RAW264.7 macrophages with ASO

In order to transfect RAW264.7 macrophages with ASO (sequence in Table 2.1),
Lipofectamine RNAiMAX was used according to the manufacturer’s instructions. Frozen
(-80oC) RAW264.7 macrophages were thawed and cultured for two days prior to
transfection. On the day of transfection, 7.0 x 105 cells were plated on 6-well plates and
stabilized for three hours. Briefly, 250 pmole of scrambled and eRNA-specific ASO were
mixed with Opti-MEM (reduced serum medium – Gibco). Simultaneously,
Lipofectamine RNAiMAX was mixed with Opti-MEM in a different vial. The two
components were mixed and incubated for 15 mins. ASO-Lipofectamine complexes were
then thoroughly deposited into respective wells, and the cells were transfected for 22
hours. Upon completion of transfection, the cells were divided into non-LPS vs LPS
groups, and re-seeded on 6-well plates. The cells were then stimulated with LPS (100
ng/mL) for 90 mins.

2.2.2
2.2.2.1

Transfection of B16-BL6 cells
Reprogramming of melanoma cells with LDTFs

B16-BL6 cells cultured for two days before being transfected. Reprogramming of B16BL6 cells initially requires transfection of the cells with LDTFs. Polyjet was employed to
transfect B16-BL6 cells according to the manufacturer’s instructions. 5.0 x 105 B16-BL6
melanoma cells were re-plated on 6-well plates and cultured in RPMI-1640 medium one
day prior to transfection. On the following day, the RPMI medium was replaced with
high glucose DMEM. 0.7 µg of control pcDNA3, pcDNA3-PU.1 and/or pBR322C/EBPα plasmids, which were generously donated by Dr. Dekoter’s lab (UWO), were
thoroughly mixed with the Polyjet media (serum-free DMEM). In another vial containing
Polyjet media, Polyjet was added and carefully mixed. The plasmid and Polyjet
containing solutions were carefully mixed and incubated for 15 mins to form plasmidPolyjet complexes. The complexes were then added into each well and incubated for 24
hours. After five hours of transfection, extra media was added into each well to lower
cytotoxicity. For eRNA and IL-1β mRNA analysis, the transfected cells were divided into
non-LPS vs LPS groups, re-plated on 6-well plates, and incubated in RPMI-1640 medium
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for another 24 hours. The LPS group was then stimulated with 100 ng/mL of LPS for 6
hours.

2.2.2.2

Introduction of ASO

For the eRNA knock-down study, the melanoma cells initially transfected with LDTFs
(post 24 hours) were divided into scrambled vs eRNA-specific ASO groups and re-plated
on 6-well plates. On the next day (48 hours post transfection), identical protocol for
transfection with LDTFs was performed to transfect the cells with 250 pmole of either
scrambled or eRNA-specific ASO for 22 hours. Once the transfection was done, the
melanoma cells were exposed to LPS (100 ng/mL) for 6 hours.

2.3

RT-qPCR

The cells were harvested upon completion of LPS stimulation for the indicated time
points. 250 µL of TRIzol was used to extract the total cellular RNA from the harvested
cells. cDNA was prepared in 20 µL reaction mixtures containing 1 µg of the isolated
RNA, dNTPs, poly-N6 (random) primers, and Moloney murine leukemia virus reverse
transcriptase. The following conditions were used for synthesis of cDNA: 65oC for 5
mins (predenaturation),25oC for 10 mins (extension), 42oC for 1 hour (cDNA synthesis),
90oC (termination). Subsequently, qPCR assays were performed with 10 µL qPCR
reaction mixtures that consisted of 1 µL of cDNA, PowerUPTM SYBR® Green Master
Mix (1X), forward and reverse primers (500 nM), and distilled water. The following
conditions were used for qPCR analyses: 50oC for 2 mins, 95oC for 2 mins, 40 cycles of
95oC for 15 secs/ 58 - 60oC for 30 secs/72oC for 20 secs/83oC for 15 secs. The RotorGene 6 software was used to generate Ct values and analyze melting curves. Expression
levels of IL-1β mRNA and eRNAs were normalized to the housekeeping gene, GAPDH,
and quantified via ∆∆Ct analysis. The sequences of GAPDH mRNA, IL-1β mRNA, and
eRNAs are listed in Table 2.1. The amplicon size of the qPCR products was examined by
gel electrophoresis.
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2.4

Droplet Digital PCR

cDNA synthesized via RT-PCR was used to measure the absolute quantities of eRNAs.
Reaction mixtures and oil droplets were generated with QX200TM ddPCRTM EvaGreen
supermix and droplet generation oil for EvaGreen, respectively, according to
manufacturer’s instructions. Initially, 25 µL reaction mixtures comprised of 1.25 µL of
cDNA, the EvaGreen supermix (1X), eRNA primer sets (100 nM), and water for
molecular biology (EMD Millipore) were prepared. The prepared reaction mixture and
the droplet generation oil were transferred into the respective wells of a DG8 cartridge.
The cartridge was loaded in the QX200 droplet generator, and the generated oil droplets
(number varies between 15,000 – 20,000 droplets) were then transferred onto a ddPCR
96-well plate, which was enclosed with heat-sealing aluminum foil. PCR was
subsequently carried out. The following conditions were used for PCR: 95oC for 5 mins
(enzyme activation), 40 cycles of 95oC for 30 secs (denaturation)/ 58oC for 1 min
(annealing/extension), 4oC for 5 mins/90oC for 5 mins (signal stabilization). Once PCR
was finished, the 96-well plate was then loaded in the QX200 droplet reader. QuantaLife
was used to analyze fluorescence measurements.

2.5

Culturing and isolating subpopulations of CRISPR cells

B16-BL6 melanoma cells were cultured for two days prior to transfection with CRISPR
editing plasmids. Polyjet was the transfection reagent used, and the same protocol as
described in section 2.2.2.1 was employed. The total amounts of CRISPR editing
plasmids used were 1.0 µg and 1.5 µg. Each group of cells were pulled and genotyped.
The remainder of the cells were frozen (-80oC). The absence or presence of the enhancer
was analyzed via gel electrophoresis. The sequences of the validation primers are listed in
Table 2.1. Then, the frozen cells (1.0 µg group) were re-cultured, and a total of 100 cells
were re-seeded on a 10 cm plate. Re-plated cells were cultured for nearly two weeks
while checking for the growth of each subpopulation daily. Once the aggregates of cells
could be seen with the naked eye, the 10 cm plate was thoroughly washed with fresh
PBS, and 2 µL of trypsin was used to detach and pick out each subpopulation of cells.
The cells were transferred onto a 24-well plate, and re-grown for another week. Once
each well reached confluency of 70-80%, the cells were harvested, genotyped, and
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analyzed for enhancer knock-out by gel electrophoresis. Single cell colonies of a
subpopulation of interest was re-analyzed using the same protocol as described above.

2.6

Chromosome Conformation Capture (3C)

The general outline of sample preparation for 3C analysis is depicted in Fig. 1.1. Initially,
a total of 1.2 x 107 cells of wild-type and LPS-stimulated RAW264.7 macrophages, and
wild-type, pcDNA3-PU.1 and/or pBR322-C/EBPα-overexpressed B16-BL6 melanoma
cells were prepared. 1.0 x 107 cells were then harvested, thoroughly washed with PBS
two times, and resuspended in 12 mL of PBS (room temperature). Formaldehyde (2%)
was added to crosslink the DNA for 10 mins at room temperature while tumbling. The
tubes were immediately put on ice after formaldehyde fixation and 1 M glycine (0.125
M) was added to terminate crosslinking. The samples were spun at 805 x g for 8 mins at
4oC. The collected pellet was washed with PBS. The samples were re-spun at 805 x g for
8 mins at 4oC. PBS was removed and the cell pellet was resuspended in 3 mL of premade lysis buffer (ice cold). The cells were lysed for 15 mins at 4oC. The lysis buffer
contained the following components: NaCl (10 mM), Tris-HCL (10 mM; pH 8.0), NP-40
(0.2%), distilled water, and cOmpleteTM, EDTA-free protease inhibitor cocktail tablet
(1X). Once finished, the lysed cells were spun down at 805 x g for 8 mins at 4oC. The
pellet of extracted nuclei was washed with PBS, and transferred to a new Eppendorf tube.
The resuspended nuclei were spun down at maximum speed for 1 min at 4oC. The
supernatant was carefully removed, and the extracted nuclei was snap-frozen in liquid N2
and stored in -80oC. Simultaneously, 2.0 x 106 cells were also harvested and resuspended
in TRIzol. In order to ensure that the prepared cells generated expected responses, IL-1β
mRNA and eRNA expression levels were analyzed in these samples prior to
digestion/ligation steps of the extracted nuclei.
Frozen nuclei were thawed and resuspended in 500 µL of 1.2x restriction enzyme (DpnII)
buffer. 20% SDS was added (final: 0.3%), and incubated at 37oC for 1 hour shaking at
1000 rpm. 20% Triton X-100 (final: 2.0%) was then added, and incubated again at 37oC
for 1 hour shaking at 1000 rpm. 10 µL of the undigested DNA was aliquoted and stored (20oC), which was used to determine the digestion efficiency. 400 U of DpnII was added
to the remainder of undigested DNA, and incubated at 37oC for 24 hours shaking at 1000
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rpm. Afterwards, 10 µL of the digested DNA was also aliquoted and stored in -20oC. Post
digestion of the DNA, 20% SDS (final: 1.6%) was added to the tube. The mixture was
incubated at 65oC for 25 mins while shaking at 1000 rpm. The digested DNA was
transferred into 50 mL falcon tubes, and 6.125 mL of the prepared ligase buffer (1.15x)
and 20% Triton X-100 (final: 1.0%) were also added. The samples were incubated at
37oC for 1 hour while tumbling. Following incubation, 800 U of T4 DNA ligase was
added and incubated at 16oC for 72 hours. Once done, the tubes were allowed to reach
room temperature, and 160 µL of 0.5 M EDTA was added to inhibit the ligase activity.
The ligated DNA was de-crosslinked with proteinase K (500 µg) at 65oC overnight. On
the following day, another 500 µg of proteinase K was added and incubated for another 2
hours. DNA was extracted with 7 mL of PCI twice and subsequently with 7 mL of
chloroform once. The tubes were centrifuged for 10 mins at room temperature at 2465 x
g. 7 mL of distilled water, 1 mL of 3M sodium acetate, and 19.25 mL of 100% EtOH
were added to the retrieved aqueous phase (7 mL), and stored at -20oC overnight. The
samples were spun at 2465 x g for 1 hour at 4oC. The pelleted DNA was washed with
70% EtOH, then briefly air-dried. 400 µL of 10 mM Tris-HCl (pH 8.0) was used to
resuspend the pellet. RNase (300 µg) was added and incubated at 37oC for 45 mins. DNA
was extracted again with 400 µL of PCI and chloroform (once each). The samples were
centrifuged at max speed for 5 mins at room temperature. Same ratio of each component
was added to the retrieved aqueous phase, and stored at -20oC for 2 hours. DNA was
pelleted by centrifuging at max speed for 30 mins at 4oC, washed with 70% EtOH, and
re-spun at same speed for 5 mins. 3C library was finally prepared by resuspending the
air-dried pellet in 200 µL of distilled water. Taqman qPCR was employed to analyze
enhancer-promoter interactions in the samples. The sequences of the primers and duallabeled Taqman probe are shown in Table 2.1. The following conditions were utilized for
Taqman qPCR: 95oC for 15 mins, 46 cycles of 95oC for 10 secs/55-58oC for 20 secs/65oC
for 40 secs.

2.6.1

Restriction Enzyme Digestion

Restriction enzyme digestion efficiency is a critical step in 3C sample preparation. In
order to determine the digestion efficiency, extracted nuclei were digested with 100 U,
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200 U, 400 U, and 600 U of DpnII. Moreover, the effect of freeze and thawing the nuclei
was examined by either freeze and thawing the sample digested with 600 U of DpnII or
immediately processing it. Instead of taking 10 µL aliquots of undigested and digested
DNA, the samples were divided in half. Other than the fact that the ligation step was
omitted, identical protocol as described above was used to prepare 3C library of
undigested and digested DNA. SYBR Green-mediated detection of fluorescence was
performed in this experiment with the same qPCR conditions used in section 2.3. The
primer sets, shown in Fig. 2.1 (sequences are listed in Table 2.1), used to determine the
digestion efficiency were designed to target either within a DNA fragment from the IL-1β
promoter or the adjacent DpnII-mediated cleavage site.

2.7

Statistical Analysis

Data were analyzed with statistical tests indicated in the figure legends. GraphPad Prism
6.0 was used to perform statistical analysis. Data are expressed as means ± S.D. (n=3).
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Table 2.1. List of sequences of ASO, qPCR primers, CRISPR validation primers, 3C
analysis primers, and restriction enzyme digestion efficiency primer.
Experiment
ASO
qPCR/ddPCR

Target
Scrambled
eRNA
GAPDH
IL-1β
534 eRNA
1251 eRNA
2258 eRNA
2860 eRNA
3236 eRNA
4152 eRNA
5370 eRNA
6212 eRNA
7182 eRNA
7951 eRNA
8453 eRNA
9013 eRNA
9236 eRNA
9486 eRNA
10368 eRNA
10841 eRNA
11743 eRNA
13252 eRNA

Primer Sequence
AACACGTCTATACGC
CAATCCTGGTTGATGA
F: GCATTGTGGAAGGGCTCATG
R: TTGCTGTTGAAGTCGCAGGAG
F: GTGGACCTTCCAGGATGAGG
R: GCTTGGGATCCACACTCTCC
F: CCTGACCCACACAAGGAAGT
R: ATGTGCGGAACAAAGGTAGG
F: TACTGCCTGCATCCATCTGC
R: GGGAGCTCTTCTTGCTTGGA
F: ATGTTGTGCAACTTGCCTGC
R: AGGAGGTTTGTCTGGGAGGA
F: ATGAGAGGGAAAGAACAGACCC
R: GCTAAGCAATGACTGTCCTCA
F: ACTTGGGGAGGAAAGGATGT
R: ATGAGGAGCAAGCCAGTGAG
F: AGTGCATGTTCCAACGTCAA
R: GACCATCAAGAACAGCAGCA
F: CTAGTCCCAGGGAGTTCTGC
R: AGGGTTAGGCGCTATGGTCT
F: CTATGGCCTATGGCTTCTGC
R: TTTTGCCACATGGCTGATAA
F: ACAGTCTCGCCACAGAAAGAA
R: CCATCAAAAGGACAACTGCAT
F: AATCACGAACAGACGACCATC
R: GCCTCCCTATCTCCCTACCTT
F: AGTAGTACCAGAGCCCCATGT
R: GCTTCCCTTTGCATCTAGCA
F: GGGTTTAAGGGTCTGGTCTTG
R: CAGAAAGCTGGGAATTGGAG
F: CATCAACCAGGATTGGACGTG
R: GCACTGGGGATCCTATTAACC
F: CGGGGAAGTGGCTGATAGTA
R: TCAGGCTTCCTTCAGTGGAT
F: ATGGAGCCCATCCCAGAG
R: AGTTACCAGCAGGGCCACTC
F: AGCCGGAGCTAAAATGGAGAC
R: CCACCACCCCAAGGACTTATC
F: AGACATTGCCCTCCAGATCC
R: CTGGGGAAAAGATGGGCAAC
F: CGCTTATGTTGGGAATTTGG
R: TCACAGAAGCAGGCAAGATG
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14256 eRNA
15232 eRNA
CRISPR
Validation
3C

Restriction
Enzyme
Digestion
Efficiency

12001 CRISPR F
11780 CRISPR R
5794 CRISPR R
Dual-labeled
Taqman probe
Universal Forward
Reverse #1
Reverse #2
Reverse #3
Reverse #4
Reverse #5
Reverse #6
Reverse #7
Reverse #8
Reverse #9
Reverse #10
Reverse #11
Reverse #12
Reverse #13
Reverse #14
Reverse #15
Reverse #16
Undigested DNA
Digested DNA

F: CCCAGGAAAGTGACGTTGTT
R: GACCTTGCTTCCACTCTTGC
F: GGCCCAGGGAGTAGCTCTAT
R: TGGAGGGGCTGAGAGTTCTA
CCCCACCAGTTATGCTATACG
CCAACAATTCAGCAAGAGCA
ACTTCATCTCCAGTTAGCCTGC
5’-JOE/TCGTTCACCACC/ZEN/
TTTGCACTGTGCAAC/BkFQ-3’
TGCTCATGAACAGGCAGATG
TTGTCTGGGAGGATTTGGAG
TCTGTAGGCAAGCCTGT
GATGCAAGTACCATGGGATG
AAAGGAAAGTGGTGTGTTTGTG
GCTGGTGGTTCTGGGTTCTA
AGGGCAACTTTGTGCAGATG
CCATCTCCTCACTCCCTTCC
GCCATCAAAAGGACAACTGC
CGACCATCAATGAGACCAAA
CTCTCCAGCACCCGTGAAT
AGACCAGACCCTTAAACCCT
TTCCGATTCACTTCCTCACC
TGCGTTGTAGTTGAAGCTGT
CTAACCCCTTCCAACACCT
GCTTACTCTGACTGCTTGCC
GTGTTCTCAGGCTGCCTTTC
F: CCTGACCCACACAAGGAAGT
R: ATGTGCGGAACAAAGGTAGG
F: TGCTCATGAACAGGCAGATG
R: TATCCCTTTTCCAGGTCTCC
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Figure 2.1. Visual representation of primer design for restriction enzyme digestion
efficiency. The image displays two adjacent DNA fragments, which have been generated
by DpnII-mediated digestion (red dotted lines), within the promoter of IL-1β. Two sets of
primers have been designed to determine the digestion efficiency of the DNA in 3C
samples. The digested (DIG F&R) primer set targets the DNA region that contains DpnII
cleavage site (5’-GATC-3’), whereas the undigested (UND F&R) primer set amplifies a
genomic region within a fragment. The PCR products produced by the DIG primers were
compared to the amplicons produced by the undigested primers, which represent
maximum amplification and were used as the control.
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Chapter 3

3

Results

3.1

Identifying the active enhancer of IL-1β in murine
macrophages

3.1.1

The genomic region with enhancer histone modifications is
macrophage-specific

As a means to identify a potential active enhancer of IL-1β, I sought for a genomic region
with enhancer-associated histone markers (H3K27Achi, H3K4me1hi, H3K4me3low) in a
100 kilobase (kbs) frame of window (± 50 kbs from IL-1β TSS). Based on the chromatin
immunoprecipitation sequencing (ChIP-seq) analysis of the chromatin markers available
in the ENCODE database as illustrated in Fig. 3.1A, I located a potential active enhancer
enriched in H3K27Ac, H3K4me1, and devoid of H3K4me3 approximately 10 kbs
upstream of the IL-1β TSS in murine bone marrow-derived macrophages (BMDMs).
Considering that enhancers are cell-type specific regulatory elements, histone
modification profiles of other cell lines including B-cell lymphomas (CH12), liver, and
brain cells were also analyzed. The non-myeloid cell lines lacked the unique histone
markers at the potential enhancer region, suggesting that the genomic region serves as a
macrophage-specific enhancer of IL-1β. Furthermore, two binding motifs of PU.1 (5’GAGGAAGT-3’; core motif highlighted in red in Fig. 3.1B), which activates
macrophage-specific enhancers in combination with other LDTFs, are located within the
putative enhancer, indicating that PU.1 potentially recognizes and binds to this regulatory
element in BMDMs.

33

Figure 3.1. A putative enhancer marked by H3K27Ac/H3K4me1/H3K4me3 within a
100 kbs window of IL1β locus in murine BMDMs. A) The ChIP-seq data from the
ENCODE database shows a putative enhancer region, which recruits high levels of
H3K27Ac and H3K4me1 and low levels of H3K4me3 in BMDMs, but not in CH12,
liver, and brain cells. B) A zoomed in image of the highlighted region shown in (A). The
highlighted region represents the position of the proposed enhancer (H3K27Achi,
H3K4me1hi, H3K4me3lo, RNAPIIhi) relative to the IL-1β TSS. The two arrows within the
putative enhancer indicate the location of PU.1 binding motif (5’-GAGGAAGT-3’).
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3.1.2

The putative genomic element produces eRNAs in response to LPS
in murine macrophages

Active enhancers recruit RNAPII, along with other transcription factors and produce
eRNAs [42,73]. As a means to examine whether eRNAs are generated from the proposed
enhancer of IL-1β, 12 qPCR primer sets that target approximately every 500-1000 bps in
genomic regions upstream, downstream, and within the putative enhancer were designed
to quantitatively measure the production of non-coding transcripts in LPS-activated
macrophages (Fig. 3.2A). Black horizontal bars show the positions of these eRNA
primers relative to the IL-1β TSS. It was observed that the expression levels of eRNAs
were dependent on the duration of macrophage exposure to LPS (Fig. 3.2B). Using 2
representative primer sets (9013, 11743), which produced greatest eRNA fold increase in
Fig. 3.2B, to further analyze eRNA production, I found that eRNAs were rapidly induced
and peaked at 90 mins post-stimulation of the macrophages, which then gradually
decreased to a basal level after 720 mins (Fig. 3.2C). Then, the kinetics of IL-1β mRNA
production in the same set of samples were examined to address whether the IL-1β
mRNA was generated in a time-dependent manner upon LPS exposure (Fig. 3.2D). I
observed a correlation between the eRNAs and IL-1β mRNA productions. The kinetics of
IL-1β mRNA production was slightly delayed in comparison to the eRNAs and reached
maximal production 180 mins after LPS stimulation.
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Figure 3.2. The production of eRNAs and IL-1β mRNA by LPS in macrophages. A)
A schematic presentation of H3K27Ac ChIP-seq peaks in BMDMs based on the the
ENCODE database and eRNA primer sets. The black horizontal bars and numerical
values indicate the location of eRNA primers and the number of base pairs upstream of
the IL-1β TSS (red arrow). B - D) RAW264.7 cells were stimulated with LPS (100
ng/mL) for the time indicated. Expression of eRNAs (B, C) and IL-1β mRNA (D) were
analyzed by RT-qPCR using GAPDH as the housekeeping gene. Fold inductions of
eRNAs and IL-1β mRNA were compared between untreated and LPS-stimulated (each
time point) RAW264.7 macrophages. The data are expressed as means ± S.D. (n=3); *, P
< 0.05, **, P < 0.05, ***, P < 0.05, Student’s t test.
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3.1.3

Measurement of LPS-induced eRNA production by droplet digital
(dd)PCR

A notable limitation of real-time PCR approach is that it only measures a relative quantity
(fold change) of template in a given primer set, and absolute quantities of template cannot
be obtained. Taking this into consideration, I used the ddPCR to measure the absolute
quantity of eRNAs (template), which allows comparison between different primer sets
[124,125]. ddPCR utilizes the power of oil droplets by partitioning a sample of DNA into
thousands of droplets. Each droplet contains all the necessary components to run a PCR
assay [126]. Thus, as opposed to detecting the fluorescence signal of a single reaction in a
standard qPCR, thousands of reactions are simultaneously carried out in a typical ddPCR
[126]. Depending on whether a copy of the target DNA is allocated in the oil droplets or
not, either a positive or a negative signal is generated, respectively [126]. Based on the
ddPCR fluorescence data in Fig 3.3A, it is apparent that there was an increase in the
number of positive droplets in LPS-stimulated macrophages. However, one factor that
must be taken into consideration when analyzing a ddPCR fluorescence data is that the
total number of oil droplets generated varies between samples. In order to overcome this
issue, the concentrations of positive droplets (unit: fluorescent droplets/µL), which were
generated via QuantaLife software, were used as the unit of measurement to make direct
comparisons between untreated and LPS-treated RAW264.7 cells (Fig. 3.3B).
Expectedly, elevated concentrations of eRNAs were observed in macrophages 60 mins
post LPS exposure. Specifically, concentrations of eRNAs detected by 8453, 9013, 9236,
9486, 10368, and 10841 primer sets were induced up to ~20-folds in LPS-stimulated
macrophages, whereas the amount of transcripts produced from the other regions
remained similar to the basal level.
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Figure 3.3. Measurement of copy numbers of eRNAs by ddPCR in macrophages
activated by LPS. A) Illustration of ddPCR fluorescence graphs for eRNA production
between wild-type and LPS-stimulated (60 mins) RAW264.7 macrophages. The blue dots
that are positioned above the threshold line (pink) represent positive droplets whereas
negative droplets are depicted as black dots. The standard RT-PCR was used to generate
cDNA from the eRNAs produced in the cells. The fluorescence of each oil droplet has
been detected via EvaGreen dye. B) Concentration of eRNAs in copies/µL (solid line)
from each sample was derived from the number of positive droplets shown in (A). The
concentration of eRNAs in LPS-stimulated macrophages was compared to the
background eRNA concentration from wild-type macrophages, and was represented as
fold changes. The dotted line represents the fold changes of eRNAs in LPS60 RAW264.7
macrophages quantified via qPCR.
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3.1.4

Examining the role of the putative eRNA in IL-1β mRNA
production

To address the role of the putative eRNA in promoting IL-1β transcription, a loss-offunction experiment was performed using the antisense locked nucleic acid (LNA™)
GapmeR (herein termed ASO). Except for a few nucleotides along the middle stretch of
the single-stranded ASO, 5’ and 3’ ends comprise LNAs, which are modified nucleotides
with an oxymethylene bridge connecting the 2’ oxygen and 4’ carbon [127]. Such
structural modifications increase the overall rigidity of the ASO [127]. Furthermore, the
DNA(ASO):RNA heteroduplex are cleaved by RNase-H that are abundant in the nucleus
[127]. Considering that eRNAs are localized in the nucleus, ASO forms a stable duplex
with target RNAs and leads to the degradation of RNAs by RNase-H [127]. Transfection
of RAW264.7 cells with the ASO targeting the putative anti-sense eRNA (eRNA-ASO;
targeting 9237-9253 bps upstream of the IL-1β TSS) suppressed 64%, 52%, and 78% of
amplicons produced from 10841, 10368, and 9486 primer sets, respectively, whereas
random ASO (scrambled-ASO) had no effect (Fig. 3.4A). Also, cells transfected with
eRNA-ASO decreased the production of IL-1β mRNA by ~50% compared to cells
transfected with scrambled-ASO (Fig. 3.4B). These results indicate that the putative
eRNA is required for optimal production of IL-1β mRNA.
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Figure 3.4. Knock-down of the putative eRNA reduces IL-1β mRNA production in
RAW264.7 macrophages. A and B) RAW264.7 macrophages were transfected with 250
pmole of scrambled-ASO or eRNA-ASO for 24 hours. These cells were then stimulated
with LPS (100 ng/mL) for 90 mins. Productions of the putative eRNA (A) and IL-1β
mRNA (B) were measured using RT-qPCR using GAPDH as the reference gene. The
data are expressed as means ± S.D. (n=3); *, P < 0.05, ***, P < 0.05, ****, P < 0.05,
Student’s t test.
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3.1.5

LPS enhances the physical interaction between the putative
enhancer and IL-1β promoter in macrophages

Enhancers are often distally positioned from the promoter region and these regulatory
elements should be brought in close proximity via chromatin looping (i.e. looping out the
intervening DNA) [128-131]. The physical interaction between these regulatory elements
has been suggested to be mediated by the interplay of eRNAs and various transcription
factors such as RNAPII and the Mediator complex [132]. Thus, I utilized the 3C
technique to examine the interaction between the putative enhancer and IL-1β promoter
in LPS-exposed RAW264.7 macrophages. Initially, the digestion efficiency of the
restriction enzyme of choice had to be determined prior to 3C sample preparation. It has
been suggested that the digestion efficiency of the chromatin should at least be 60-70%,
as low digestion efficiency can generate inaccurate quantification results [122]. I decided
to use the restriction enzyme DpnII, which recognizes 5’-GATC-3’ and cleaves before G,
that renders ~500 bp size genomic DNA fragments. First, I optimized the digestion
condition by testing varying amounts of DpnII to yield ≥ 70% digestion efficiency (Fig.
3.5) [133,134]. I found that the minimum amount of DpnII required to reach ~70%
digestion efficiency was 400 U. Next, I found that the crosslinked DNA should go
through a round of freeze (-80oC) and thaw cycle prior to digestion to increase the
digestion efficiency by ~25%.
Through 3C-TaqMan qPCR analysis, I found that the interaction between the IL-1β
promoter and proximal fragments occurred in both non-treated and LPS-treated (180
min) macrophages (Fig. 3.6 B, C). As the DNA is not in linear form and is densely
packaged in the nucleus, the promoter and the proximal fragments are likely situated in
proximity in the nuclear space. Since 3C measures the ligation frequencies between
fragments based on their proximity, the ligation between the promoter and the proximal
fragments in untreated and LPS-stimulated RAW264.7 cells likely occurred by chance
and was considered as background interaction. However, we observed that the ligation
between the promoter of IL-1β with both 3’- and 5’-ends of the putative enhancer
occurred upon stimulation of macrophages with LPS for 180 mins (Fig. 3.6C), which was
absent in wild-type cells (Fig. 3.6B). The grey upright bars represent the frequency of
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interaction between the IL-1β promoter and the crosslinked genomic fragment. It is
important to note that Fig. 3.6C only displays new enhancer-promoter interactions
detected upon LPS challenge. Overall, these results are a clear indication that enhancerpromoter interactions are stimulus-dependent in murine macrophages.
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Figure 3.5. Optimization of restriction enzyme digestion for 3C analysis. RAW264.7
cells (1.0 x 107) were fixed with formaldehyde for crosslinking of interacting DNA
regions and then the genomic DNAs were extracted. Extracted DNAs were digested with
varying amounts of DpnII (100, 200, 400, 600 U), and the DNAs digested with 600 U of
DpnII underwent a round of freezing and thawing (FT; NFT: No FT). Digested DNA
fragments were de-crosslinked with proteinase K and subsequently extracted. Digestion
efficiency was measured via qPCR with primer sets targeting undigested and digested
genomic regions.
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Figure 3.6. LPS stimulation induces enhancer-promoter interaction in macrophages.
A) Dotted lines represent possible cleavage sites by DpnII (400 U), and arrows indicate
the primers used to probe the digested DNA fragments. Each reverse primer (black) was
utilized in combination with the promoter-recognizing universal forward primer (red). B
and C) RAW264.7 cells were treated with none (A) or LPS for 180 mins (B) and fixed by
formaldehyde. DNAs were then digested with DpnII (400 U) and ligated for 72 hours.
The physical interaction between the regulatory elements were quantified via TaqMan
qPCR. The arrows extending from the IL-1β promoter to the DNA fragments generated
by DpnII indicate the occurrence of ligation. The upright bars represent the ligation
frequencies between the promoter and interacting DNA fragments, which have been
compared to the ligation frequency of two adjacent DNA fragments in the promoter
region.
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3.2
3.2.1

Examining the role of PU.1 in the enhancer-promoter
regulatory network of IL-1β
Overexpression of PU.1 is sufficient for inducing IL-1β mRNA
expression in B16-BL6 murine melanoma cells

Rapid production of IL-1β in response to microbial infection is a feature of innate
immune cells, such as macrophages, and this unique phenotype is likely due to regulatory
elements that allow prompt transcriptional initiation triggered by extracellular signals. As
shown in Fig. 3.1, the macrophages harbor an active enhancer (H3K27Achi, H3K4me1hi,
H3K4me3low), which is not detected in other cell lines. Since LDTFs play key roles in
determining cell identities, I have examined the role of LDTFs involved in macrophage
differentiation including PU.1 and C/EBPα in regulating the putative enhancer for IL-1β.
As shown in Fig. 3.7A, transfection efficiency of B16-BL6 melanoma cells is very high,
as mRNA expression levels of PU.1 and C/EBPα increased by ~40000- and ~500000fold, respectively, compared to vector control (VC) transfected cells. Furthermore, B16BL6 cells are able to activate the mitogen-activated protein kinases (MAPKs:
extracellular regulated kinases (ERKS) and p38 MAPK) within 60 mins in response to
LPS (Appendix A). Therefore, these cells could be an ideal system to examine the role of
LDTFs in regulating IL-1β production. As shown in Fig. 3.7B, ectopic expression of
PU.1 rendered these cells to express IL-1β mRNA in response to LPS. In contrast,
C/EBPα overexpression did not induce the production of IL-1β mRNA. Concomitant
expression of PU.1 and C/EBPα did not change IL-1β mRNA expression levels when
compared to cells overexpressed with PU.1 alone. These results suggest that PU.1 alone
is sufficient for rendering B16-BL6 melanoma cells to produce IL-1β in response to LPS.
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Figure 3.7. The production of IL-1β mRNA in response to LPS is dependent on the
overexpression of PU.1 in B16-BL6 melanoma cells. A) B16-BL6 cells were
transfected with VC or PU.1 and/or C/EBPα (0.7 µg each) plasmids for 48 hours. The
expression levels of PU.1 and C/EBPα were analyzed via qPCR, and normalized to
GAPDH. Data are expressed as means ± S.D. (n=3); *, P < 0.05, **, P < 0.05, Student’s t
test. B) B16-BL6 cells were ectopically expressed with the same plasmids as described in
(A) and stimulated with LPS (100 ng/mL) for 6 hours. IL-1β mRNA production was
quantified via qPCR. Data are expressed as means ± S.D. (n=3); ***, P < 0.05, Student’s
t test.
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3.2.2

Overexpression of PU.1 induces the activation of the putative IL1β enhancer

Since overexpression of PU.1 rendered B16-BL6 cells to induce IL-1β mRNA expression
(Fig. 3.7B), I have examined whether PU.1 overexpression also activated the putative
enhancer found in macrophages (Fig. 3.1). As shown in Fig. 3.8A, overexpression of
B16-BL6 cells with either PU.1 alone or PU.1 and C/EBPα induced basal level of eRNA
transcription prior to LPS stimulation, whereas C/EBPα had a minimal effect.
Subsequently, I investigated the effect of LPS stimulation on eRNA production in cells
ectopically expressing either PU.1, C/EBPα or both PU.1 and C/EBPα. Fig. 3.8B displays
that LPS increased the production of transcripts by approximately 3-fold from regions
targeted by 14236, 13252, 9486, and 8453 primer sets. The greatest fold increase (~10fold) in eRNA was detected by the 10841 primer set. Similar to IL-1β mRNA data,
C/EBPα did not have much contribution in promoting transcription of eRNAs in response
to LPS (Fig. 3.8C). Moreover, combination of PU.1 and C/EBPα generally increased the
production of eRNAs upon LPS stimulation (Fig. 3.8D); however, most of these fold
increases turned out to be statistically insignificant. Interestingly, LPS-induced eRNAs
detected by 11743 and 10841 primer sets in PU.1- and C/EBPα-overexpressed cells
elevated by ~4-fold.
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Figure 3.8. eRNAs are readily produced in PU.1-overexpressed B16-BL6 melanoma
cells in response to LPS. A-D) B16-BL6 cells were overexpressed with PU.1 and/or
C/EBPα (0.7 µg each) for 48 hours, then either unstimulated or stimulated with LPS (100
ng/mL) for 6 hours. The production of eRNAs in cells transfected with VC, PU.1,
C/EBPα, or both LDTFs was measured via qPCR prior to LPS stimulation (A). Fold
changes in eRNA production were compared between unstimulated or LPS stimulated
B16-BL6 cells overexpressed with PU.1 (B), C/EBPα (C), or both LDTFs (D).
Production of eRNAs was quantified by qPCR. GAPDH was the housekeeping gene used
to analyze eRNA expression. Data are expressed as means ± S.D. (n=3); **, P < 0.05,
***, P < 0.05, ****, P < 0.05, Student’s t test.
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3.2.3

Examining the role of the putative IL-1β regulatory element by
gene editing

To address the role of the putative enhancer identified through the ENCODE database,
the regulatory element was edited out using the clustered regularly interspaced short
palindromic repeats (CRISPR)-Cas9 system in B16-BL6 cells as shown in Fig. 3.9A. The
two guide RNA sequences with the protospacer adjacent motif (PAM; 3 bases
highlighted in red) in the 3’-ends were designed to be complimentary to genomic regions
upstream and downstream of the putative enhancer. Cas9-mediated cleavage of the DNA
was expected to yield two blunt ends that would be repaired via the non-homologous end
joining (NHEJ) pathway. To confirm that the genome has been edited, the forward primer
(Fig. 3.9A: red arrow), which is complimentary to the sequences of the 5’-side of the
genomic NHEJ product, was used in combination with either the 11780 (inner) or 5794
(outer) reverse primers that target the un-edited or edited 3’-side of the genomic NHEJ
products, respectively. The amplicons produced by the inner primer set (241 bps)
indicates failure to generate DNA double strand breaks and intact enhancer region,
whereas amplicons produced by the outer primer set (296 bps) infers successful knockout of the enhancer and repairing of the genome. I initially analyzed the PCR products
using these primer sets in wild-type and B16-BL6 cells transfected with two different
amounts (1 and 1.5 µg; herein termed CR1 and CR1.5) of the CRISPR editing plasmids. I
found that only the inner amplicons were detected in non-transfected wild-type cells (Fig.
3.9B), which was an expected finding as the genomic region that spans the enhancer
targeted by the outer primer set is too large to be amplified under the same PCR
conditions (6229 bps). In contrast, both of the inner and outer primer sets yielded
amplicons with expected sizes in cells transfected with the CRISPR editing plasmids
(Fig. 3.9B). These results indicated that the gene-edited cells were likely heterogeneous
cell populations that consisted of cells harboring the genomic sequences of the edited and
un-edited regulatory element. Therefore, I selected 9 single colonies from these cells and
re-analyzed for the enhancer knock-out. Among them, one colony (#4) showed PCR
products from both inner and outer primers while only PCR products from the inner
primers were detected in all of the other colonies (Fig. 3.9C). To further examine if
colony #4 originated from a single cell, cells were sub-cloned and re-analyzed for the
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genome edition status. PCR amplicons from the inner and outer primers were detected in
all the 8 sub-colonies examined (Fig. 3.9D), suggesting that the colony contains a
homogenous cell population harboring only one allele with successful gene editing.

3.2.3.1

Monoallelic deletion of the putative regulatory element
compromises the production of IL-1β eRNAs and mRNA

To examine the role of the putative regulatory element in eRNA and IL-1β mRNA
production, cells harboring the monoallelic regulatory element and wild-type cells were
transfected with PU.1 for 48 h, then stimulated with LPS for 6 h. Cells with the
monoallelic regulatory element produced significantly lower amount of eRNAs than cells
with intact regulatory element based on qPCR assays using the 11743, 10841, 10368, and
9486 primer sets (Fig. 3.10A). In line with these results, expression of IL-1β mRNA was
significantly reduced by ~70% in cells with monoallelic regulatory element than control
cells (Fig. 3.10B).
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Figure 3.9. Genetic deletion of the putative regulatory element by a CRISPR-Cas9
vector in B16-BL6 cells. A) Visual representation of the relative locations of CRISPRCas9-mediated cleavage sites, and primer sets used to validate the deletion of the
enhancer region in B16-BL6 cells. PCR products of 241 and 296 bp sizes using the
combination of the forward primer (12001: red arrow) and the inner (11780: black arrow)
or the outer (5794: black arrow) reverse primers suggest unsuccessful and successful
deletion of the putative regulatory element, respectively. The sequences 5’AAATGCCAGCGCCCTGAGAG-3’ and 3’-AGGCAAATTCAATGGGAATG-5’ are
complimentary to the gRNAs used, and the 3 bp DNA sequences highlighted in red
indicate the PAM sequence. B) The PCR products amplified by the inner and outer
primer sets were analyzed in wild-type and B16-BL6 cells transfected with CRISPR
editing plasmids (1, 1.5 µg). Detection of bands for inner primer and outer primer sets
indicate the presence or absence of the putative regulatory element, respectively. C and
D) Gel electrophoresis analyses of the PCR amplicons from CR1(C)- and colony #4(D)derived single colonies. Identical validation system described in (A) and used in (B) were
employed to confirm the success of genome edition.

63

A)
5’-AAATGCCAGCGCCCTGAGAG-AGG-3’

Cas9

3’-GGG-AGGCAAATTCAATGGGAATG-5’

Cas9

Enhancer

TSS

Outer [296 bps]
12001 11780

5794

Inner [241 bps]

B)
WT

CR1 CR1.5 WT CR1 CR1.5

1K
750
500
250

Inner
(1838/1565)

Outer
(1838/1839)

C)
WT

#1

#2

#3

#4

#5

#6

#7

#8

#9

WT

1K
750
500

1K
750
500

250

250

Outer
(1838/1839)

#1

#2

#3

#4

#5

Inner
(1838/1565)

#6

#7

#8

#9

64

D)
WT

#1

#2

#3

#4

#5

#6

#7

#8

WT

#1

#2

#3

#4

#5

1K
750
500

1K
750
500

250

250

Outer
(1838/1839)

Inner
(1838/1565)

#6

#7

#8

65

Figure 3.10. Monoallelic deletion of the putative regulatory element compromises
the productions of eRNAs and IL-1β mRNA. A and B) PU.1 (0.7 µg) was transfected
in wild-type and B16-BL6 cells with the monoallelic regulatory element with the
transfection reagent Polyjet for 48 hours, then stimulated with LPS (100 ng/mL) for 6
hours. Cells were harvested and cDNA was prepared with RT-PCR. The qPCR amplicons
of the eRNAs (A) using 11743, 10841, 10368, and 9486 primer sets and IL-1β mRNA
(B) were analyzed. Data are expressed as means ± S.D. (n=3); *,p < 0.05,**,p < 0.05,
****,p < 0.05, Student’s t test.
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3.2.4

Knocking-down the putative eRNA suppresses IL-1β mRNA
expression

To further examine the role of the eRNA produced in B16-BL6 cells, I first knocked
down the eRNA using the ASO as described in Section 3.1.4. In line with previous
results, LPS stimulation induced eRNA transcription by approximately 5-20 fold in PU.1overexpressing B16-BL6 cells, and eRNA-ASO suppressed the production of eRNAs
based on primer sets 10841, 10368, and 9486 by approximately 71%, 76.5%, and 76%,
respectively (Fig. 3.11A). Also, IL-1β mRNA production in LPS-stimulated cells with
the eRNA knocked-down was almost fully abolished (Fig. 3.11B), suggesting that the
eRNAs also play a critical role in IL-1β mRNA expression in B16-BL6 cells expressing
PU.1.
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Figure 3.11. eRNAs regulate LPS-induced IL-1β response in PU.1-overexpressed
melanoma cells. A and B) B16-BL6 cells were overexpressed with PU.1 (0.7 µg) for 48
hours, then re-transfected with scrambled- or eRNA-ASO (250 pmole) for 24 hours.
Upon completion of transfection, PU.1-overexpressed B16-BL6 cells were exposed to
LPS (100 ng/mL) for 6 hours. Expression levels of eRNAs (A) and IL-1β mRNA (B)
were analyzed by qPCR. Data are expressed as means ± S.D. (n=3); *, P < 0.05, **, P <
0.05, ***, P < 0.05, Student’s t test.
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3.2.5

PU.1 orchestrates the interaction between the putative IL-1β
regulatory element (enhancer) and promoter independent of
stimulatory signal

We identified that our proposed genomic region serves as an enhancer of IL-1β by
examining the characteristics that are required to define an enhancer. Specifically, PU.1dependent activation of the enhancer induces the production of eRNAs, which contribute
in the regulation of IL-1β. The ability of PU.1 to control the expression level of IL-1β
piqued our interest in other potential methods of gene regulation. Hence, enhancerpromoter interactions were measured via 3C-TaqMan qPCR analysis to determine
whether or not local chromatin landscape of IL-1β is altered as a consequence of PU.1
overexpression. To begin with, Fig. 3.12A shows that we detected basal level ligation
between proximal fragments and the promoter of IL-1β in wild-type B16-BL6 cells,
which likely occurred due to chance. Interestingly, we were also able to detect the
interaction between the IL-1β promoter with a fragment ~15 kbs away, indicating that
these regions are closely situated in the nuclear space. We then explored the role of PU.1
in promoting the formation of enhancer-promoter interactions (Fig. 3.12B). It is
noteworthy that diagrams for LDTF-overexpressed cells only displays additional
interactions that we detected on top of the interactions that occurred in the wild-type
cells. Dissimilar to the case in wild-type melanoma cells, abundance of PU.1 induced
chromatin looping between the enhancer and the promoter. Like macrophages, LPS
stimulation of PU.1-overexpressed cells also enhanced the ligation frequency between the
regulatory elements (Fig. 3.12C), suggesting that re-organization of the chromatin
landscape is stimulus-dependent. Furthermore, ectopic expression of C/EBPα in B16BL6 cells caused minimal ligation between the enhancer and the promoter (Fig. 3.12D).
Since C/EBPα is not involved in promoting the generation of IL-1β mRNA and eRNAs,
we speculated that the chromatin structure between unstimulated and stimulated C/EBPαoverexpressed cells would not differ; thus, 3C sample of stimulated cells was omitted and
not prepared.
Next, we also quantitatively analyzed the effect of LPS treatment in promoting the
interaction between the enhancer and the promoter in B16-BL6 cells overexpressed with
both LDTFs. In agreement with cells that were solely transfected with PU.1, concomitant
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expression of PU.1 and C/EBPα caused greater number of enhancer fragments to
associate with the promoter of IL-1β upon LPS exposure (Fig. 3.12E, F). Finally, we
examined the interaction between the regulatory elements in our CRISPR cell line (PU.1overexpressed) with partial knock-out of the enhancer region. Although we expected
reduced occurrence of enhancer-promoter interactions in CRISPR cells, we were still able
to observe that the intact enhancer region physically associated with the IL-1β promoter
via PU.1-mediated chromatin re-organization (Fig. 3.12G).
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Figure 3.12. Overexpression of PU.1 induces physical interaction between the IL-1β
enhancer and promoter. A-G) 3C-Taqman qPCR using the same combinations of
primers as described in Fig. 3.6 was used to examine the enhancer-promoter interaction
frequencies in wild-type, LDTF-overexpressing, and genome edited B16-BL6 cells.
Wild-type B16-BL6 melanoma cells (A), cells that were transfected with PU.1 and/or
C/EBPα (0.7 µg each; B-F), and cells with monoallelic regulatory element transfected
with PU.1 (0.7 µg; G) were either unstimulated or stimulated with LPS (100 ng/mL) for 6
hours. The cells were harvested, underwent formaldehyde crosslinking, and lysed. The
extracted nuclei were digested with 400 U of DpnII for 24 hours and subsequently ligated
for 72 hours. The overarching arrows in (B-G) represent additional interactions between
fragments with the IL-1β promoter that were detected on top of the background
interactions shown in wild-type B16-BL6 cells (A). The bars in each diagram represent
the frequencies of interaction between the promoter region targeted by the universal
forward primer and any DNA regions that localize with the promoter in the nuclear
space.

73

A)
WT
TSS

Enhancer

TSS

Enhancer

TSS

Enhancer

TSS

Enhancer

TSS

Ligation
Frequency

Enhancer

B)
PU.1

Ligation
Frequency

C)
PU.1 + LPS

Ligation
Frequency

D)
C/EBPa

Ligation
Frequency

E)
PU.1, C/EBPa

Ligation
Frequency

74

F)
PU.1, C/EBPa + LPS
TSS

Enhancer

TSS

Ligation
Frequency

Enhancer

G)
CRISPR, PU.1

Ligation
Frequency

75

3.3
3.3.1

Elucidating the role of PU.1 domains in the IL-1β regulatory
network
Examining the role of PU.1 domains in IL-1β eRNA and mRNA
expression

It has been shown that PU.1 has four distinct domains: acidic, Gln-rich, PEST, and Ets
(DNA binding) [99,135]. Fig. 3.13A illustrates the locations of these domains and
constructs of PU.1 mutant plasmids obtained from Dr. Dekoter at UWO. To examine the
role of each domain, wild-type PU.1 and its mutants were transfected in B16-BL6 cells,
and production of IL-1β mRNA and the putative eRNA were analyzed. Cells transfected
with PU.1 mutant plasmids lacking either the acidic (Δ2-30, Δ33-74) or the Gln-rich
(Δ75-100) domain or with the mutated Ets domain (PU.1R230, 233A: 230th and 233rd
arginine residues have been replaced with alanine) failed to produce IL-1β mRNA in
response to LPS, whereas cells transfected with the mutant lacking the PEST domain
(Δ118-167) produced IL-1β mRNA to the same extent as cells transfected with wild-type
PU.1 (Fig. 3.13B). Although changes in eRNA production was not as drastic as those of
mRNA, a similar trend was observed where the levels of eRNA expression induced
remained consistent in cells transfected with PU.1WT and PU.1 118-167, but the levels were
Δ

substantially reduced in cells transfected with PU.1 2-30, PU.1 33-74 , PU.1 75-100 and
Δ

Δ

Δ

PU.1R230, 233A (Fig. 3.13C). These results suggest that the acidic, Gln-rich and Ets
domains of PU.1 are required by the cells to generate IL-1β in response to LPS.
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Figure 3.13. LPS-induced production of IL-1β is dependent on the acidic, Gln-rich,
and Ets domains of PU.1. A) A schematic of PU.1 domains and the constructs of PU.1
mutant plasmids. Domains are represented by each coloured block; acidic (blue), Glnrich (green), PEST (yellow), and Ets (red). B and C) B16-BL6 cells were transfected with
PU.1 WT (1 µg) or PU.1 mutant (PU.1 2-30, PU.1 33-74 , PU.1 75-100, PU.1 100, PU.1 118-167,
Δ

Δ

Δ

Δ

Δ

PU.1R230, 233A) plasmids for 48 hours, then stimulated with LPS (100 ng/mL) for 6 hours.
The production of IL-1β mRNA (A) and eRNAs (B) were analyzed by qPCR. Data are
expressed as means ± S.D. (n=2); *, P < 0.05, **, P < 0.05, ***, P < 0.05 ANOVA.
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3.3.2

Examining the involvement of PU.1 domains in the IL-1β
enhancer-promoter interaction

In section 3.2.5, I showed that overexpression of PU.1 promoted the interaction between
the enhancer and the promoter. To further examine the involvement of each PU.1 domain
in the IL-1β enhancer-promoter interaction, B16-BL6 cells were transfected with wildtype and various mutants (PU.1 33-74, PU.1 75-100, PU.1 100, PU.1 118-167, and PU.1R230, 233A)
Δ

Δ

Δ

Δ

of PU.1. The interaction between the enhancer and the promoter in the reprogrammed
B16-BL6 cells was analyzed via 3C-TaqMan qPCR only using the primers that target the
five fragments within the putative enhancer. Expectedly, overexpression of PU.1WT in
B16-BL6 cells restructured the genome to cause the enhancer and the promoter of IL-1β
to interact (Fig. 3.14A). Similar to PU.1WT-transfected cells, the enhancer-promoter
interaction in melanoma cells ectopically expressed with PU.1 mutants remained intact
(Fig. 3.14B-F), as majority of the fragments that spanned the enhancer ligated with the
IL-1β promoter. Although only the PU.1 118-167 mutant induced the IL-1β eRNA and
Δ

mRNA (Fig. 3.13) while all other PU.1 mutants were unable to do so, the extent of the
enhancer-promoter interaction in PU.1 33-74-, PU.1 75-100-, and PU.1 118-167-overexpressed
Δ

Δ

Δ

cells did not change when compared to that of cells transfected with wild-type PU.1 (Fig.
3.14B, C, E). Interestingly, simultaneous knock-out of the acidic and Gln-rich domains
(PU.1 100) resulted in decreased enhancer-promoter interaction frequency. These data
Δ

suggest that both the acidic and Gln-rich domains of PU.1 act in concert to reorganize the
chromatin while the PEST domain is dispensable for the enhancer-promoter interaction.
Similar to the PU.1 100 mutant, mutation in the DNA binding domain (PU.1R230, 233A) also
Δ

disrupted the interaction between the regulatory elements; which was an expected
finding, as such mutation can inhibit PU.1 binding to the DNA. Furthermore, in order to
compare the enhancer-promoter interaction frequencies between samples from Fig. 3.14,
the ligation frequencies between individual fragments in the putative enhancer with the
IL-1β promoter were summed. As illustrated in Fig. 3.14G, the interaction between the
enhancer and the promoter of IL-1β were significantly reduced in melanoma cells
ectopically expressed with PU.1 100 and PU.1R230, 233A; indicating that not only do
Δ

acidic/Gln-rich and DNA binding domains have roles in gene transactivation and DNA
binding capacity of PU.1, respectively, but also partake in chromatin organization.
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Figure 3.14. The acidic, Gln-rich, and DNA binding domains of PU.1 mediate IL-1β
enhancer-promoter interaction. A-F) PU.1 (A) or PU.1 mutant (domains deleted:
acidic – B, Gln-rich – C, acidic & Gln-rich – D, PEST – E, domain mutated: DNA
binding – F) was overexpressed in B16-BL6 melanoma cells. Upon completion of the 48
hour transfection period, 3C library was prepared from cells that underwent a cycle of
crosslinking, restriction enzyme digestion (400 U DpnII) and ligation. The physical
association of the enhancer and the promoter was quantified via TaqMan qPCR. The
black arrows in (A-F) represent the occurrence of ligation between fragments positioned
within the putative enhancer with the IL-1β promoter. The upright grey bars in each
diagram represent the frequencies of interaction between the promoter region and the
distal enhancer fragments. G) The quantitative values of ligation frequencies represented
as bars in (A-F) were totaled and compared. The ligation frequency between the enhancer
and the promoter of IL-1β in B16-BL6 cells overexpressed with wild-type PU.1 was used
as the control. Data are expressed as means ± S.D. (n=2); *, P < 0.05, **, P < 0.05,
ANOVA.
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Chapter 4

4

Discussion

In this study, I proposed that the genomic region located ~10 kbs upstream of the IL-1β
TSS is an enhancer regulating the expression of IL-1β, based on histone modification
markers: H3K27Achi, H3K4me1hi, and H3K4me3low (Fig. 3.1). It has been suggested that
eRNAs are dynamically transcribed as a consequence of enhancer activation [136].
Therefore, I first examined whether the genomic region produced eRNAs in response to
LPS in RAW264.7 cells (Fig. 3.2B, C). Upon LPS treatment, eRNA(s) was rapidly
generated and reached a peak level in 90 mins, which was earlier than that of IL-1β
mRNA that reached maximal production at 180 mins post LPS stimulation (Fig. 3.2D).
These results were consistent with previous studies showing that transcription of
enhancers precede production of mRNAs [137-139]. Specifically, de Santa et al.
demonstrated that transcripts generated from genomic regions with enhancer-specific
chromatin signatures (H3K4me1hi and H3K4me3low) upstream of the chemokines,
chemokine ligand 5 (Ccl5) and C-X-C motif chemokine 11 (Cxcl11), were detected at an
earlier time point than mRNAs in LPS-stimulated macrophages [138]. They employed
ChIP-seq to show that the production of these transcripts was the result of LPS-induced
binding of Ser5P (phosphorylated Serine 5 of CTD) RNAPII at the genomic regions
[138]. Furthermore, another study demonstrated that transcription of enhancers preceded
their proximal promoters in various cell types including stem cells, differentiating
committed progenitor cells, and terminally differentiated primary cells [137]; suggesting
that early transcription of eRNAs is a general phenomenon and can be a necessity for
upregulation of target genes. Thus, the rapid production of the putative eRNA before the
advent of IL-1β mRNA may suggest a role of the eRNA in IL-1β mRNA expression. I
examined the role of the putative eRNA in IL-1β mRNA expression using the anti-sense
eRNA targeting ASO (Fig. 3.4). Through successful knock-down of the eRNA, the
expression of IL-1β mRNA was also suppressed; inferring that the eRNA is not just a byproduct of enhancer transcription, but is a functionally important molecule involved in
the regulation of IL-1β. My results were in line with several other studies that also
showed that suppression of eRNAs by short hairpin (sh) RNA, siRNA, and ASO reduced
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their cognate gene transcription [80,140,141]. In particular, Lam et al. demonstrated that
the expression levels of matrix metallopeptidase 9 (Mmp9) and CX3C chemokine
receptor 1 (Cx3cr1) genes were attenuated upon ASO-mediated inhibition of Mmp9 and
Cx3cr1 eRNAs, respectively, in BMDMs [115]. Furthermore, they engineered a reporter
plasmid that comprised the Mmp9 enhancer upstream of the Mmp9 promoter, which
controlled the Luc expression [115]. When the sequence of the sense eRNA was removed
from the Mmp9 enhancer, Lam et al. reported that the Luc expression decreased, whereas
the presence or the absence of the antisense eRNA sequence did not affect the activity of
the Mmp9 promoter [115]; concluding that the Mmp9 enhancer regulates the transcription
of Mmp9 gene via eRNAs in a strand- and orientation-dependent manner. Considering
that eRNAs can be transcribed bi-directionally, knock-down of the sense eRNA
transcribed from the IL-1β enhancer can address whether or not eRNA-mediated
regulation of IL-1β is orientation-specific. Moreover, through ddPCR experiments I
showed that high levels of eRNA production were detected in the central region (between
primer sets 8453-10841) of the enhancer (Fig. 3.3B). In addition, eRNA detected by 9013
and 11743 primer sets did not increase to the same extent as shown in the qPCR data,
suggesting that the actual eRNA produced from the putative regulatory element could be
an uni-directional long non-coding RNA approximately 2500 bps in size. However, this
speculation is inconsistent with the current notion that the median length of eRNAs is
~350 bps [94]. Not only that, ChIP-seq analysis of RNAPII in Fig. 3.1 illustrates that
RNAPII is dispersed (mainly enriched at two distinct regions) within the H3K27Acenriched enhancer region. Taking into account that LPS exposure of macrophages
resulted in the enrichment of Ser5P RNAPII at enhancers, it is highly probable that the
pre-docked RNAPII at the enhancer are paused, which are eventually converted into the
elongation phase upon cell activation. Therefore, I surmise that the transcripts generated
from the enhancer are not uni-directional, but are rather bi-directional transcripts that
vary in size and orientation (sense and antisense).
Another checkpoint that needed to be fulfilled in order to label the proposed genomic
region as an enhancer was that the distal enhancer and the promoter must be in the
vicinity of one another irrespective of any intervening DNA [129,142,143]. Here, I found
that the local chromatin landscape of IL-1β was altered, and the enhancer-promoter
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interaction was established in a stimulus (LPS)-dependent manner in macrophages (Fig.
3.6C). This observation is in line with a previous study that demonstrated the
communication between the IL-1β promoter with another potential enhancer (~3 kbs
upstream of TSS) in LPS-exposed macrophages [144], suggesting that an extracellular
stimulus is required and necessary to remodel the chromatin architecture of IL-1β.
Despite the fact that low levels of IL-1β are constitutively expressed in macrophages,
remodeling of the chromatin architecture, which brings distal regulatory elements into
proximity, is absolutely necessary for rapid induction of IL-1β. There are multiple factors
that are involved in the formation of enhancer-promoter interactions. For example, Lai et
al. reported that shRNA-mediated knock-down of MED1 and MED12 subunits abolished
the interaction between the zinc finger protein SNAI1 gene and its enhancer in HEK293
cells [110]. Another group has highlighted the role of cohesin in establishing enhancerpromoter interactions by depleting the cohesin subunit, double-strand-break repair protein
(RAD21), in MCF-7 cells stimulated with 17β oestradiol; essentially abrogating the
interaction between the regulatory elements of the nuclear receptor-interacting protein 1
(NRIP1) gene [80]. Intriguingly, the mediator complex and cohesin tend to co-occupy
enhancers and promoters, and it has been shown that the recruitment of these protein
complexes is mediated by eRNAs [80,110,119]. In this study, I saw a correlation between
the enhancer-promoter ligation frequency and eRNA production in LPS-stimulated
macrophages, potentiating the role of eRNAs in remodeling the chromatin landscape of
IL-1β via recruitment of the Mediator complex and cohesin.
It is generally believed that a cell-type specific repertoire of enhancers is chosen by
various LDTFs [145]. It has been shown that nucleosome depletion and subsequent
recruitment of LDTFs to putative enhancers are events that occur prior to the deposition
of unique chromatin signatures like H3K4me1hi and H3K4me3low [145,146]. Specifically,
PU.1 is a LDTF that has the ability to select macrophage-specific enhancers [146], which
induce the upregulation of genes essential for macrophage differentiation and function.
Previously, it was shown that overexpression of PU.1 and C/EBPα transdifferentiated the
NIH 3T3 murine fibroblast cells into macrophage-like cells that displayed macrophage
morphology, and acquired the ability to produce cytokines and phagocytose bacteria
[147]. This led me to hypothesize that enhancers of IL-1β are recognized and activated by
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PU.1. In order to determine whether or not activation of the enhancer is PU.1-dependent,
I took an alternative approach and used non-myeloid B16-BL6 cells that do not produce
IL-1β mRNA but respond to LPS (Appendix A, Fig. 3.7B). I found that ectopic
expression of PU.1 in the B16-BL6 cells induced eRNA and IL-1β mRNA transcription
upon exposure to LPS (Fig. 3.8B, 3.7B). Additionally, through CRISPR-Cas9-mediated
knock-out of the enhancer followed by PU.1 overexpression, I observed reduced
expression of eRNAs and IL-1β mRNA (Fig. 3.10), suggesting that the genomic region
serves as the enhancer of IL-1β. Moreover, ASO-mediated knock-down of the eRNA
inhibited IL-1β expression (Fig. 3.11). These results indicate that PU.1, which drives
macrophage differentiation at high concentrations [102], recognized and opened up the
macrophage-specific IL-1β enhancer in B16-BL6 cells. It has been reported that PU.1
promotes the deposition of H3K4me1 and recruitment of p300 at enhancers in
macrophages [103,104]. Furthermore, stimulation of macrophages induces the binding of
p65 (active subunit of NF-κB) at PU.1/p300 co-occupied, and H3K4me1-enriched
enhancer regions [65]; suggesting that LPS-induced production of eRNAs in PU.1overexpressed B16-BL6 cells is the result of these sequence of intracellular events.
Conversely, C/EBPα had minimal impact on the production of both transcripts, which is
expected as abundance of C/EBPα is associated with the development of granulocytes
and neutrophils [107,108]. However, the role of C/EBPα should not be neglected as low
level of endogenous C/EBPα mRNA was detected in B16-BL6 cells (data not shown).
Since majority of macrophage-specific enhancers tend to be co-occupied by PU.1 and
C/EBP family of proteins [86,148,149], which recruit p65 most efficiently [129], it is
likely that both LDTFs are required for the activation of the IL-1β enhancer.
Moreover, I utilized 3C analysis to investigate the role of LDTFs in reorganizing the
chromatin landscape, specifically resulting in the formation of IL-1β enhancer-promoter
interactions, whether it be solely under the influence of PU.1, C/EBPα or the combination
of the two LDTFs. It has previously been shown that PU.1 has the capacity to remodel
the chromatin architecture and mediate enhancer-promoter interactions [130,150]. For
example, PU.1 is able to autoregulate itself by binding to a distal enhancer (~14 kbs
upstream of the PU.1 TSS) and bridging its physical association with the PU.1 promoter
in hematopoietic stem cells and macrophages [150]. Likewise, as presented in Fig. 3.12B,
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I found that the physical association of the IL-1β enhancer and promoter occurred upon
ectopic expression of PU.1 in B16-BL6 cells. The PU.1-dependent association of the
regulatory elements was absent in RAW264.7 macrophages, indicating that higher
concentration of PU.1 may be required for the enhancer-promoter interaction to be preformed. Furthermore, C/EBPα also had the capacity to bridge the interaction between the
enhancer and the promoter (Fig. 3.12D), which was an unexpected finding because this
TF did not render the B16-BL6 cells to express IL-1β (Fig. 3.7B). Enhancer-promoter
interactions in C/EBPα-overexpressed cells could have emerged due to low levels
endogenous PU.1 in the cells, which could be generated by C/EBPα-mediated activation
of the PU.1 promoter and distal enhancer [151,152]. These results indicate that both
LDTFs, whether directly or indirectly, partake in the formation of enhancer-promoter
interactions prior to LPS challenge. Moreover, similar to macrophages, LPS stimulation
of the reprogrammed melanoma cells increased the interaction frequency between the IL1β regulatory elements. This observation signifies that the the enhancer-promoter
interaction in the IL-1β regulatory network is stimulus-dependent, and supports the
potential involvement of eRNAs is mediating the communication between the regulatory
elements.
PU.1 is a 271 amino acid long protein with four distinct domains. Since PU.1 is deemed
the master regulator of IL-1β transcription in the reprogrammed B16-BL6 cells, I was
interested in examining the role of each PU.1 domain in promoting the expression of IL1β eRNAs and mRNA, as well as enhancer-promoter interactions. As the PU.1 mutants
had contrasting effects on the overall production of IL-1β mRNA and eRNAs (Fig.
3.13B, C), we predicted that the frequency of enhancer-promoter interactions
orchestrated by these PU.1 variants would also differ. To our surprise, there was no
significant change in how frequently the regulatory elements of IL-1β ligated in cells
overexpressed with the PU.1 variants, despite complete abrogation of IL-1β mRNA and
eRNAs in PU.1 33-74- and PU.1 75-100-transfected cells (Fig. 3.14). Most interestingly,
Δ

Δ

concomitant knock-out of the acidic and Gln-rich domains of PU.1 (PU.1 100) attenuated
Δ

the interaction between the enhancer and the promoter of IL-1β. Thus, these findings lead
to the conclusion that single domains of PU.1 are not responsible for the establishment of
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chromatin looping between the enhancer and the promoter, but are dictated by the
cooperation of two domains in the N-terminus of PU.1. Reorganization of the chromatin
landscape mediated by the acidic and Gln-rich domains could potentially be an
underlying mechanism of their ability to transactivate genes. Furthermore, there are other
potential candidates that could collaborate with PU.1 to rearrange the chromatin. The first
group of candidates is HATs such as CBP and p300, which directly interact with the Glnrich domain of PU.1 [153,154]. Although the role of HATs in enhancer-promoter
interactions has not yet been demonstrated, they are transcription co-factors that colocalize with pioneer factors and acetylate unique residues of histones [47,81].
Specifically, Whalen et al. exemplified the enrichment of H3K27Ac at interacting
regulatory elements [155], which extends the possibility that the proteins responsible for
the deposition of such chromatin signature may be essential for the interaction to occur.
Brd4, a protein that contains 2 bromodomains, is the other candidate that could bring the
regulatory elements into vicinity. It has been postulated that Brd4 binds enhancers (cooccupied by PU.1) and promoters to promote transcription [156,157]. The Brd-4-specific
inhibitor, JQ1, could be used to suppress Brd-4 mediated generation of the putative
eRNA to study its role in chromatin remodeling. Lastly, it has been demonstrated that
5hmC, the oxidized metabolite of 5mC, accumulates at enhancers and is associated with
enhancer activity [158,159]. Hon et al. has previously shown that Tet2-mediated
conversion of 5mC to 5hmC at enhancers correlated with binding of various TFs such as
Oct4 and Sox2 in mouse embryonic stem cells [158]. Interestingly, PU.1 is able to
physically interact and recruit Tet2, possibly suggesting that hypomethylated state of
regulatory elements may contribute in chromatin reorganization [160].
In summary, I identified an enhancer of IL-1β that lies ~10 kbs upstream of the TSS. This
particular enhancer was activated by PU.1, which serves as the pioneer transcription
factor that recruits other necessary components to initiate transcription of the putative
eRNA in response to LPS stimulation. Most notably, in the presence of abundant PU.1,
intra-chromosomal interaction between the enhancer and the promoter was formed,
which was further enhanced upon stimulation of the cells with LPS. Fig. 4.1 illustrates
my working model of PU.1 and IL-1β enhancer-promoter looping formation. This study
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unraveled the mechanisms by which PU.1 regulates the expression of IL-1β in response
to LPS stimulation.

4.1

Clinical significance and therapeutic treatment

The concept of chromatin architecture has recently garnered attention as it adds a layer of
complexity in gene regulation. Thorough analysis of how the chromatins are organized
can be used to define the overall state or identity of cells. For example, taking into
account that a repertoire of enhancers is cell-type specific, malignant cells with unique
gene expression profiles will display enhanced physical association between the
regulatory elements of highly active genes; thus, our knowledge of chromatin architecture
can be considered as a preventive measure. This is also applicable in our attempt to
regulate the expression of IL-1β. In many IL-1β-induced diseases, we can analyze
whether or not the uncontrolled expression of the cytokine is caused by high interaction
frequency between our proposed enhancer and the promoter. If so, considering that
eRNAs are one of the determinants of enhancer-promoter interactions [80,110,111],
sequence-specific ASO can be employed to target the eRNAs and disrupt their activity.
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Figure 4.1. Schematic representation of how the IL-1β regulatory network is
modulated by PU.1. Enhancer-promoter interactions are pre-formed at high
concentrations of PU.1. PU.1 has an additional role of recruiting p300/CBP and Tet that
can deposit epigenetic marks such as H3K27Ac and 5hmC on histones and cytosine,
respectively. Acetylated lysines of histone H3 are recognized by Brd4, which activates PTEFb to initiate transcription of IL-1β eRNA and mRNA.
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4.2
4.2.1

Future studies
Identifying other active enhancers of IL-1β via 3C-derivative
experiments

It is widely accepted that multiple enhancers work in concert to trigger transcription of
genes. However, the ability of enhancers to function over long distances makes it
challenging for investigators to pinpoint their cognate genes. This study used 3C-TaqMan
qPCR to quantitatively analyze the physical association between the IL-1β enhancer and
promoter. A disadvantage of 3C analysis is that only known sequences of the captured
fragment (enhancer) and the bait (promoter) are examined [161]; thus, this particular
technique cannot be utilized for genome-wide studies. In order to overcome the limit, 3Cderivative experiments such as 4C (3C-seq; 3C followed by next generation sequencing)
has gained popularity in recent years. Therefore, 3C is often described as a one-to-one
approach and 4C is a one-to-all approach [162]. In contrast to using a single 4-cutter
restriction enzyme in 3C, two rounds of digestion are performed in 4C [163]. The
primary digestion step, which involves digestion of the crosslinked DNA with a 6-cutter
restriction enzyme and a subsequent ligation step, is followed by a secondary
digestion/ligation step to generate small circular DNA [162,163]. The ligated capturedbait fragments are then amplified with bait-specific primers via PCR, and the resulting
products are sequenced through NGS [162,163]. Our lab has performed 4C analysis using
IL-1β promoter as the bait and identified 5 other genomic locations that formed intrachromosomal interactions (Appendix B). These interactions now can be confirmed by 3C
analysis or reverse 4C (using the candidate enhancers as the bait).

4.2.2

Elucidating the role of epigenetic modifiers in IL-1β regulation

The level of histone acetylation is determined by the interplay between HATs and
HDACs [164-166]. Histone acetylation initiates depletion of nucleosomes, rendering
DNA accessibility to various transcription factors [167]. For example, Frank et al.
showed that inhibition of HDACs results in remarkable changes in chromatin
accessibility and PU.1 preferentially associated with euchromatin [168]. Although the
dynamic switch from euchromatin to heterochromatin is dictated by HDACs, the ability
of these histone modifiers to remodel the chromatin architecture on a genome-wide scale
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has not yet been determined. Our lab showed that HDAC8, a member of class I HDACs,
selectively deacetylates H3K27Ac [169]. In addition, the diminished levels of H3K27Ac
are in line with reduced eRNA and IL-1β mRNA production [169]. Considering that
H3K27Ac is a unique marker of active enhancers, I speculate that the mechanism of
HDAC8 in regulating IL-1β expression is likely through enhancing the enhancerpromoter interaction. Since I identified the IL-1β enhancer, it will be interesting to
examine whether HDAC8 is involved in the enhancer-promoter interaction through 3C
analysis in macrophages. We expect that overexpression of HDAC8 will abolish the
enhancer-promoter interaction; whereas, HDAC8 inhibition will result in higher
frequency of the interaction.

4.2.3

Examining the mechanism of macrophage tolerance

As previously mentioned, plasticity and heterogeneity are hallmarks of macrophages.
Tissue-resident macrophages are scattered throughout the body, and have the capacity to
generate appropriate responses according to the environmental cues [170,171]. Amongst
many stimuli that foster cell-type specific responses, prolonged exposure to LPS can
result in the development of a phenomenon known as LPS tolerance [172,173]. In this
hyporesponsive state, macrophages become refractory to a secondary LPS challenge
[173,174]. Another notable environmental stimulus that suppresses macrophage
activation is the probiotic strain such as Lactobacillus rhamnosus GR-1 [175]. Similar to
LPS-tolerated macrophages, pre-exposure of macrophages to L. rhamnosus GR-1
abrogated expression of IL-1β. Granulocyte colony stimulating factor (G-CSF), which is
well-known for its involvement in the generation of neutrophils, is an immunoregulatory
cytokine that leads macrophages to immunomodulatory cells [176,177]. Contrastingly,
recent discoveries documented that macrophages can be converted into nonspecific innate
memory cells upon initial exposure to β-glucan [178]. In this trained state, macrophages
have acquired the ability to generate a stronger response to secondary stimuli [178,179].
Interestingly, increased responsiveness of trained macrophages is the product of elevated
H3K27Ac and H3K4me3 levels at distal enhancers and promoters, respectively
[178,180]. Epigenetic reprogramming of innate memory cells raises the possibility that
macrophage tolerance is regulated via similar epigenetic mechanisms. Furthermore, such
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phenotypic variance of macrophages prompts us to investigate if different activity states,
particularly in regards to IL-1β production, are affected by enhancer-promoter
interactions; which can be determined through 3C-Taqman qPCR. We speculate that
macrophage training is largely associated with enhanced interaction between the
regulatory elements while LPS-, GR-1-, and G-CSF-mediated tolerance will show
opposing results. These findings could be directly linked to epigenetic reprogramming of
the genome, and various histone modifiers can be targeted to modulate chromatin
reorganization.
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Appendices
Appendix A: LPS-stimulation induces activation of MAPKs in wild-type and PU.1-,
C/EBPα-overexpressed B16-BL6 cells. Expression levels of phospho-p38, phosphoERK, and phospho-IκB in wild-type and PU.1-, C/EBPα-overexpressed (transfected 0.7
µg of each plasmid with Polyjet for 48 hours) B16-BL6 cells untreated or treated with
LPS (100 ng/mL) for 1, 2, or 3 hours were analyzed by Western blots. Β-actin was used
for loading controls. Data in Appendix A were generated by Dr. Soon-Duck Ha.
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Appendix B: 4C analysis of inter- and intra-chromosomal interactions between the
IL-1β promoter and potential enhancers scattered in the genome. A) Circos plot
displays physical association of the IL-1β promoter with enhancers localized in different
chromosomes of activated macrophages. LPS-stimulated RAW264.7 macrophages were
harvested and crosslinked with formaldehyde. Two cycles of restriction enzyme digestion
and ligation were performed in 4C. The extracted DNA was sequenced with Illumina
sequencing. B) Computational analysis of the raw sequencing data also generated a
spider plot to display the intra-chromosomal interactions detected in activated
macrophages. Data in Appendix B were generated by Dr. Soon-Duck Ha and Jeremy
Wong.
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